<SEC-DOCUMENT>0001683168-24-007907.txt : 20241112
<SEC-HEADER>0001683168-24-007907.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112165546
ACCESSION NUMBER:		0001683168-24-007907
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20241110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RadNet, Inc.
		CENTRAL INDEX KEY:			0000790526
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				133326724
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33307
		FILM NUMBER:		241449477

	BUSINESS ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025
		BUSINESS PHONE:		3104787808

	MAIL ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIMEDEX HEALTH SYSTEMS INC
		DATE OF NAME CHANGE:	19930518

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCC FRANCHISING CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>radnet_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:RDNT="http://radnet.com/20241110">
<head>
     <title>RadNet, Inc. 8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_RDNT_radnet.com_20241110 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20241110_20241110 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0000790526 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000004" name="dei:EntityCentralIndexKey">0000790526</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rdnt-20241110.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000790526</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-10</xbrli:startDate>
        <xbrli:endDate>2024-11-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">UNITED
STATES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Washington,
D.C. 20549</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 15%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 12pt"><b>FORM
<span id="xdx_908_edei--DocumentType_c20241110__20241110_z1NDsEBN7gX2"><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 15%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date
of Report (Date of earliest event reported) <b><span id="xdx_90D_edei--DocumentPeriodEndDate_c20241110__20241110_zrIuXP0PVYbf"><ix:nonNumeric contextRef="AsOf2024-11-10" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November
10, 2024</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90B_edei--EntityRegistrantName_c20241110__20241110_zMAzmsh4EODi" style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000011" name="dei:EntityRegistrantName">RadNet,
Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 10pt; width: 32%"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20241110__20241110_zP59bxxsz8e4" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-11-10" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; padding-left: 10pt; width: 32%"><span id="xdx_90B_edei--EntityFileNumber_c20241110__20241110_zmhhiLAGvKfb" style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000013" name="dei:EntityFileNumber">001-33307</ix:nonNumeric></b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 32%"><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20241110__20241110_zStn8b5Eh4w8" style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000014" name="dei:EntityTaxIdentificationNumber">13-3326724</ix:nonNumeric></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">(State or other jurisdiction<br/>
    of incorporation)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(IRS Employer Identification No.)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 49%"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20241110__20241110_zmKXUbupQ4xe"><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000015" name="dei:EntityAddressAddressLine1">1510 Cotner Avenue</ix:nonNumeric></span></b></td>
  <td style="width: 2%">&#160;</td>
  <td style="text-align: center; width: 49%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1pt solid; text-align: center"><b><span id="xdx_909_edei--EntityAddressCityOrTown_c20241110__20241110_zLJAmxB9ZQUg"><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000016" name="dei:EntityAddressCityOrTown">Los
  Angeles</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20241110__20241110_zzTPMye2V8j"><ix:nonNumeric contextRef="AsOf2024-11-10" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: center"><b><span id="xdx_900_edei--EntityAddressPostalZipCode_c20241110__20241110_z5JOeHu61Yy2"><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000018" name="dei:EntityAddressPostalZipCode">90025</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center">(Address of Principal Executive Offices)</td>
  <td>&#160;</td>
  <td style="text-align: center">(Zip Code)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <b>(<span id="xdx_90A_edei--CityAreaCode_c20241110__20241110_zUbPpQGdC6vj"><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000019" name="dei:CityAreaCode">310</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20241110__20241110_zYkFR9H37EQ"><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000020" name="dei:LocalPhoneNumber">478-7808</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Registrant&#8217;s
Telephone Number, Including Area Code</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"/><td style="width: 21.5pt"><span id="xdx_901_edei--WrittenCommunications_c20241110__20241110_zG0uSZ1jpuQ3" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-11-10" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"/><td style="width: 21.5pt"><span id="xdx_90D_edei--SolicitingMaterial_c20241110__20241110_zbwxKxtvHljb" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-11-10" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"/><td style="width: 21.5pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20241110__20241110_z8PokMJVcAZ5" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-11-10" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"/><td style="width: 21.5pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20241110__20241110_zJaSEF8WLiYi" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="AsOf2024-11-10" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 35%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
                                            of each class</b></span></p></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span id="xdx_906_edei--Security12bTitle_c20241110__20241110_zWFpYiW31KZk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000025" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value</ix:nonNumeric></span></td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_908_edei--TradingSymbol_c20241110__20241110_zAANF8y53ega" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-11-10" id="Fact000026" name="dei:TradingSymbol">RDNT</ix:nonNumeric></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span id="xdx_90B_edei--SecurityExchangeName_c20241110__20241110_zzBx6T5WdO02" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2024-11-10" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20241110__20241110_zEcS8hehHEOk"><ix:nonNumeric contextRef="AsOf2024-11-10" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in">Item 2.02</td><td>RESULTS OF OPERATIONS AND FINANCIAL CONDITION</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 10, 2024 RadNet,
Inc. (&#8220;RadNet&#8221;) issued a press release and, on November 11, 2024, held a conference call regarding its 2024 financial results
for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and a copy of the transcript
of the conference call is furnished as Exhibit 99.2 to this Current Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this Current
Report, including Exhibit 99.1 and Exhibit 99.2 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report,
including Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any registration statement or other document filed
with the Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 9.01</b></td><td style="text-align: justify"><b>FINANCIAL STATEMENTS AND EXHIBITS</b></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 12%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Exhibit No.</span></b></span></td>
    <td style="width: 88%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Description of Exhibit</span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>


<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-weight: normal"><a href="radnet_ex9901.htm">Press
Release dated November 10, 2024 relating to RadNet, Inc.&#8217;s financial results for the quarter and full fiscal year ended
September  30, 2024.</a></span></p>
</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>99.2</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-bottom: 0pt"><span style="font-weight: normal"><a href="radnet_ex9902.htm">Transcript of conference call.</a></span></p>
</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">104</span></td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></td></tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><b></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 99.1pt 0 98.85pt; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 12, 2024</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RADNET, INC.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 53%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 40%; text-align: center">&#160;</td>
    <td style="width: 2%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark D.
    Stolper</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Name:</td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark  D. Stolper</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>Title:</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer </span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 12%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Exhibit No.</span></b></span></td>
    <td style="width: 88%"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Description</span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>


<tr style="vertical-align: top">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"><span style="font-weight: normal"><a href="radnet_ex9901.htm">Press
        Release dated November 10, 2024.</a></span></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>99.2</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: -2.5in"><span style="font-weight: normal"><a href="radnet_ex9902.htm">Transcript of conference call.</a></span></p>
</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">104</span></td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fm2igvZNi4pYRYqIr8FuJdhmyyb+HclbGlvEZWFZZr4ZIXpiRUtTIcNpnmdwwLqptEfIsURGe8bgSNebBMLN8WKcZ219+/7AlAKDgRn3ldJBaK1347BIIB4N5GSgRiBlMpzCbCuir56SLU2B1htdgbYF7JkaNug1v7qEg36SpfrVVh2RnSGbgOzHnfwGFUsFO7rrB/HVQZalIuq1E4kV060JrsXTo/2SsKiwDnWuo/8bfQABzEqE -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>radnet_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: red"><B><IMG SRC="image_004.jpg" ALT="" STYLE="height: 74.25pt; width: 172.5pt"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RadNet Reports Third Quarter Financial Results with Record Quarterly
Revenue and Adjusted EBITDA<SUP>(1)</SUP> and Revises Upwards 2024 Financial Guidance Ranges </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Total
Company Revenue increased 14.7% to $461.1 million in the third quarter of 2024 from $402.0 million in the third quarter of 2023; Revenue
from the Digital Health reportable segment (inclusive of intersegment revenue) increased 34.3% to $16.4 million in the third quarter
of 2024 from $12.2 million in the third quarter of 2023</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Digital
Health Revenue growth resulted in part from a $2.2 million (or 75.8%) increase in AI Revenue, which climbed to $5.1 million during the
third quarter of 2024 from $2.9 million in the third quarter of 2023</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext"><I>Total
Company Adjusted EBITDA<SUP>(1) </SUP>was $73.7 million in the third quarter of 2024 as com</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">pared
with $57.9 million in the third quarter of 2023, an increase of 27.2%; </FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext">Digital
Health reportable segment Adjusted EBITDA<SUP>(1)</SUP> increased 41.7% to $3.3 million in the third quarter of 2024 from $2.3 million
in the third quarter of 2023</FONT></I></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Total
Company Adjusted EBITDA<SUP>(1)</SUP> margins increased by 156 bps to 16.0% in the third quarter of 2024 as compared with 14.4% in the
third quarter of 2023</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol; color: windowtext">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><I>Adjusting
for unusual or one-time items in the quarter, Adjusted Diluted Earnings Per Share<SUP>(3)</SUP> was $0.18 for the third quarter of 2024;
This compares with Adjusted Earnings Per Share<SUP>(3)</SUP> of $0.13 for the third quarter of 2023</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Aggregate
procedural volumes in the third quarter of 2024 increased 9.0% and same-center procedural volumes increased 5.5% compared with the third
quarter of 2023</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>As
of September 30, 2024, we had a cash balance of $748.9 million and Net Debt to Adjusted EBITDA<SUP>(1)</SUP> ratio of below 1.0x</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>On
pace for the commercial launch of DeepHealth OS on December 1<SUP>st</SUP> at the Radiological Society of North America (RSNA) conference</I></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>RadNet
revises full-year 2024 guidance levels to increase Revenue, Adjusted EBITDA<SUP>(1)</SUP> and Free Cash Flow<SUP>(2)</SUP> ranges</I></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LOS ANGELES, California, November 10, 2024
&ndash; RadNet, Inc. (NASDAQ: RDNT),</B> <FONT STYLE="color: black">a national leader in providing high-quality, cost-effective, fixed-site
outpatient diagnostic imaging services through a network of 399 owned and operated outpatient imaging centers</FONT>, today reported financial
results for its third quarter of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer of RadNet, commented, &ldquo;We continue to demonstrate strong growth and record results in each of our Imaging Center and Digital
Health reportable operating segments. Total Company Revenue grew 14.7% as compared with last year&rsquo;s third quarter to a record $461.1
million. The Digital Health segment Revenue of $16.4 million increased 34.3% from last year&rsquo;s same quarter. The strong growth in
Digital Health was, in part, driven by the AI businesses, whose Revenue increased 75.8% as compared with last year&rsquo;s third quarter,
mainly from the continuing success of the rollout of the Enhanced Breast Cancer Detection (EBCD) DeepHealth AI-powered screening mammography
program.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Despite continued inflation in staffing
costs, improved reimbursement from commercial and capitated payors, strong demand for advanced imaging modalities, the growth of the Digital
Health businesses and effective cost controls resulted in an increase to Adjusted EBITDA<SUP>(1)</SUP> margins. Total Company Adjusted
EBITDA<SUP>(1)</SUP> margin of 16.0% during this third quarter increased by 156 basis points over last year&rsquo;s third quarter.&rdquo;
added Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Given the positive trends we continue to
experience in virtually all aspects of our business and the strong financial performance of the third quarter, we are revising upwards
certain guidance levels in anticipation of financial results that we believe will exceed both our original expectations and the adjustments
we made to the guidance ranges upon releasing our first and second quarter 2024 results. We have increased 2024 guidance ranges for Revenue,
Adjusted EBITDA<SUP>(1)</SUP> and Free Cash Flow<SUP>(2)</SUP>,&rdquo; added Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Berger continued, &ldquo;In response to continued
high demand for our services and notable patient backlogs in many of RadNet&rsquo;s local markets, we continue to expand capacity through
the development and construction of new imaging centers. Since the start of the year, we have opened five new centers, and we anticipate
opening an additional three centers before year end. Furthermore, we have 15 centers in various stages of construction and development
which we intend to open during 2025.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We remain on pace for the commercial launch
of DeepHealth OS at the RSNA convention this year taking place December 1<SUP>st</SUP> through 4<SUP>th</SUP> in Chicago. At our DeepHealth
booth, we will be demonstrating the capabilities of the DeepHealth OS integrated end-to-end workflow solutions as well as our clinical
AI tools. Last week, we announced our first customer for the DeepHealth OS software platform, and we are eager to introduce our DeepHealth
solutions to prospective customers and partners at the convention, explained Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;RadNet&rsquo;s balance sheet continues
to strengthen as our focus remains on driving same-center revenue performance and effective cost management. At quarter end, we had a
cash balance of $748.9 million, and our leverage ratio of Net Debt to Adjusted EBITDA<SUP>(1)</SUP> was at a record low, slightly below
1.0,&rdquo; concluded Dr. Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Third Quarter Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the third quarter of 2024, RadNet reported
Total Company Revenue of $461.1 million and Adjusted EBITDA<SUP>(1)</SUP> of $73.7 million. Revenue increased $59.2 million (or 14.7%)
and Adjusted EBITDA<SUP>(1)</SUP> increased $15.7 million (or 27.2%) as compared with the third quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the third quarter of 2024, RadNet reported
Digital Health Revenue (inclusive of intersegment revenue) of $16.4 million and Adjusted EBITDA<SUP>(1)</SUP> of $3.2 million. Revenue
increased $4.2 million (or 34.3%) and Adjusted EBITDA<SUP>(1)</SUP> increased $950,000 (or 41.7%) as compared with the third quarter of
2023. Digital Health Revenue and Adjusted EBITDA<SUP>(1)</SUP> growth was due in part from a $2.2 million (or 75.8%) increase in AI Revenue,
which climbed to $5.1 million during the third quarter of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unadjusted for unusual or one-time items impacting
the third quarter, Total Company Net Income for the third quarter of 2024 was $3.2 million as compared with a Total Company Net Income
of $17.5 million for the third quarter of 2023. Fully diluted Net Income Per Share <FONT STYLE="color: black">for the third quarter of
2024 was $0.04, compared with a fully diluted Net Income per share of $0.25 in the third quarter of 2023, based upon a weighted average
number of diluted shares outstanding of 75.2 million shares in 2024 and 68.8 million shares in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">There were a number
of unusual or one-time items impacting the third quarter including: </FONT>$8.1 million of non-cash loss from interest rate swaps; <FONT STYLE="color: black">$304,000
in severance expense related to cost-savings initiatives; $1.3 million expense related to leases for de novo facilities under construction
that have yet to open their operations; $3.3 million of non-capitalized research and development expenses related to the DeepHealth Cloud
OS and generative AI; $417,000 of acquisition transaction costs; and $147,000 loss in conjunction with extinguishment of debt and related
expenses. Adjusting for the above items, Total Company Adjusted Earnings<SUP>(3)</SUP> was $13.3 million and diluted Adjusted Earnings
Per Share<SUP>(3)</SUP> was $0.18 during the third quarter of 2024. This compares with Total Company Adjusted Earnings<SUP>(3)</SUP> of
$8.8 million and diluted Adjusted Earnings Per Share<SUP>(3)</SUP> of $0.13 during the third quarter of 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the third quarter of 2024, as compared with
the prior year&rsquo;s third quarter, MRI volume increased 14.6%, CT volume increased 15.5% and PET/CT volume increased 23.8%. Overall
volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 9.0% over the
prior year&rsquo;s third quarter. On a same-center basis, including only those centers which were part of RadNet for both the third quarters
of 2024 and 2023, MRI volume increased 9.9%, CT volume increased 9.8% and PET/CT volume increased 16.8%. Overall same-center volume, taking
into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 5.5% over the prior year&rsquo;s
same quarter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Nine Month Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first nine months of 2024, RadNet reported
Total Company Revenue of $1,352.6 million and Adjusted EBITDA<SUP>(1)</SUP> of $204.5 million. Revenue increased $156.3 million (or 13.1%)
and Adjusted EBITDA<SUP>(1)</SUP> increased $37.9 million (or 22.8%) as compared with the first nine months of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the first nine months of 2024, RadNet reported
Digital Health Revenue (inclusive of intersegment revenue) of $46.9 million and Adjusted EBITDA<SUP>(1)</SUP> of $10.0 million. Revenue
increased $12.0 million (or 34.4%) and Adjusted EBITDA<SUP>(1)</SUP> increased $6.3 million (or 171.6%) as compared with the first nine
months of 2023. Digital Health Revenue and Adjusted EBITDA<SUP>(1)</SUP> growth was due in part to a $8.0 million (or 107.8%) increase
in AI Revenue, which climbed to $15.4 million during the nine month period of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unadjusted for one-time or unusual items, Total
Company Net Loss for the first nine months of 2024 was $2.6 million as compared with a Total Company Net Income of $4.9 million for the
first nine months of 2023. Fully diluted Net Loss Per Share <FONT STYLE="color: black">for the nine month period of 2024 was $(0.04),
compared with a Net Income per share of $0.08 in the nine month period of 2023, based upon a weighted average number of diluted shares
outstanding of 72.6 million shares in 2024 and 63.2 million shares in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>2024 Guidance Update</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RadNet amends its previously announced guidance
levels as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Imaging Center Segment</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt"></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Original Guidance <BR>
Range</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Revised Guidance<BR>
 Range After <BR>
Q1 Results</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Revised Guidance <BR>
Range After<BR>
 Q2 Results</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Revised Guidance <BR>
Range After<BR>
 Q3 Results</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 20%; text-align: justify">Total Net Revenue</TD><TD STYLE="width: 1%"></TD>
    <TD STYLE="width: 19%; text-align: justify">$1,650 - $1,700 million</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: justify">$1,675 - $1,725 million</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: justify">$1,685 - $1,735 million</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: justify">$1,710 - $1,760 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Adjusted EBITDA<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$250 - $260 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$255 - $265 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$257 - $267 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$262 - $270 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Capital Expenditures<SUP>(a)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$125 - $135 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$130 - $140 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$135 - $145 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$145 - $155 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cash Interest Expense<SUP>(b)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$40 - $45 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$37 - $42 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$32 - $37 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$25 - $30 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Free Cash Flow <SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$65 - $75 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$68 - $78 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$72 - $80 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">$83 - $93 million</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify">(a)</TD><TD STYLE="text-align: justify">Net of proceeds from the sale of equipment, imaging centers and
joint venture interests and New Jersey Imaging Network capital expenditures.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify">(b)</TD><TD STYLE="text-align: justify">Includes payments to and from counterparties on interest rate
swaps and nets interest income from our cash balance as recorded in Other Income.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Digital Health Segment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Original Guidance<BR>
 Range</TD><TD STYLE="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Revised Guidance<BR>
 Range After <BR>
Q1 Results</TD><TD STYLE="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Revised Guidance<BR>
 Range After <BR>
Q2 Results</TD><TD STYLE="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Revised Guidance<BR>
 Range After<BR>
 Q3 Results</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 28%; text-align: left">Total Net Revenue (inclusive of intersegment revenue)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 17%; text-align: center">$60 - $70 million</TD><TD STYLE="text-align: center; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 17%; text-align: center">$60 - $70 million</TD><TD STYLE="text-align: center; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 17%; text-align: center">$60 - $70 million</TD><TD STYLE="text-align: center; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 17%; text-align: center">$60 - $70 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Adjusted EBITDA<SUP>(1)</SUP> Before Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$12 - $14 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$13 - $15 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$13 - $15 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$13 - $15 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$11 - $13 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$12 - $14 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$12 - $14 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$13 - $15 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Capital Expenditures<SUP>(i)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$3 - $5 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$3 - $5 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$3 - $5 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$3 - $5 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Free Cash Flow<SUP>(2)</SUP> Before Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$8 - $10 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$8 - $10 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$8 - $10 million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$8 - $10 million</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Free Cash Flow<SUP>(2)</SUP> After Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$(2) - $(5) million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$(2) - $(5) million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">$(2) - $(5) million</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">$(2) - $(5) million &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left">(i)</TD><TD>Excludes a $9 million purchase of software code and other intellectual
property from a vender.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Based upon
the consistent outperformance of the first three quarters of this year relative to our projections, we have increased guidance ranges
of our core Imaging Center reporting segment for Revenue and Adjusted EBITDA</FONT><FONT STYLE="color: black"><SUP>(1)</SUP></FONT><FONT STYLE="font-size: 10pt">.
Furthermore, despite increasing the Capital Expenditures guidance range by $10 million, we are expecting Free Cash Flow<FONT STYLE="color: black"><SUP>(2)</SUP></FONT>
to be higher for the year. This is the result of the projected increase in Adjusted EBITDA<SUP>(1)</SUP> and lower Cash Interest Expense.
With respect to the Digital Health reportable segment, we remain on track to meet our original guidance levels for Revenue, <FONT STYLE="color: black">Adjusted
EBITDA<SUP>(1) </SUP></FONT> and Free Cash Flow<SUP>(2)</SUP>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call for Tomorrow</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Howard Berger, President and Chief Executive
Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its third quarter
2024 results on Monday, November 11th, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conference Call Details:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: Monday, November 11, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time: 10:30 a.m. Eastern Time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dial In-Number: 844-826-3035</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">International Dial-In Number: 412-317-5195</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">It is recommended
that participants dial in approximately 5 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived
webcasts available at </FONT>https://viavid.webcasts.com/starthere.jsp?ei=1691984&amp;tp_key=8cbf05cc88
<FONT STYLE="font-size: 10pt">or http://www.radnet.com under the &ldquo;Investors&rdquo; menu section and &ldquo;News Releases&rdquo;
sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S.,
or 412-317-6671 for international callers, and using the passcode 10193306.</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>About RadNet, Inc.</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RadNet, Inc., is the leading national provider
of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence)
in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient
imaging centers. RadNet&rsquo;s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition,
RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand and other related
products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time
and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit http://www.radnet.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>Forward Looking Statements</I></B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and
strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified
by words such as: &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;goal,&rdquo; &ldquo;seek,&rdquo; &ldquo;believe,&rdquo;
&ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;strategy,&rdquo; &ldquo;future,&rdquo; &ldquo;likely,&rdquo;
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; and similar references to future periods. Forward-looking statements in this
press release include, among others, statements about our anticipated business results, balance sheet and liquidity and our future liquidity,
burn rate and our continuing ability to service or refinance our current indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">Forward-looking statements are neither historical
facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties,
risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and
financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue
reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking statements include, among others, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
availability and terms of capital to fund our business;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to service our indebtedness, make principal and interest payments as those payments become due and remain in compliance with
applicable debt covenants, in addition to our ability to refinance such indebtedness on acceptable terms;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes
in general economic conditions nationally and regionally in the markets in which we operate;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
availability and terms of capital to fund the expansion of our business and improvements to our existing facilities;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">our ability to acquire, develop, implement
and monetize technology, digital health initiatives, artificial intelligence algorithms and applications;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">volatility
in interest and exchange rates, or credit markets;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
adequacy of our cash flow and earnings to fund our current and future operations;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes
in service mix, revenue mix and procedure volumes;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays
in receiving payments for services provided;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">increased
bankruptcies among our partner physicians or joint venture partners;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
impact of the political environment and related developments on the current healthcare marketplace and on our business, including with
respect to the future of the Affordable Care Act;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement
thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for our services,
or other material impacts to our business;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">closures
or slowdowns and changes in labor costs and labor difficulties, including stoppages affecting either our operations or our suppliers'
abilities to deliver supplies needed in our facilities;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
occurrence of hostilities, political instability or catastrophic events;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 20pt"></TD><TD STYLE="width: 20pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">noncompliance
by us with any privacy or security laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation,
loss or other unauthorized use or disclosure of confidential information.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any forward-looking statement contained in this
current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of
changed circumstances, new information, future developments or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation G: GAAP and Non-GAAP Financial
Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release contains certain financial information
not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes
that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes
this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in
the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should
not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled
measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial
information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this
release in the tables which follow.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>CONTACTS: </I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>RadNet, Inc.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mark Stolper, 310-445-2800</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Executive Vice President and Chief Financial
Officer</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; width: 66%; text-align: left">Cash and Cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">748,916</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">342,570</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">199,076</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,707</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Due from affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,342</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38,051</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">47,657</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,016,253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">579,276</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">663,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">604,401</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease right-of-use assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">646,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">596,032</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total property, plant, equipment and right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,310,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,433</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">711,841</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">679,463</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Other intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,643</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Investment in joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,514</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,710</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Deposits and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45,260</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,333</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,275,342</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,690,473</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts payable, accrued expenses and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">338,737</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">342,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Due to affiliates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,872</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,910</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,392</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,647</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Current operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,751</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,981</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Current portion of notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,378</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,974</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">470,130</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">437,452</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG-TERM LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Long-term operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">658,434</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">605,097</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Notes payable, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">996,272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">812,068</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred tax liability, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,776</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other non-current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,077</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,721</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,155,708</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,877,114</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 0pt; text-align: left">RadNet, Inc. stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Common stock - $0.0001 value, 200,000,000 shares authorized; 73,976,284 and 67,956,318 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Additional paid-in-capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">979,279</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">722,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,843</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,484</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(82,130</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(79,578</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Total RadNet, Inc.'s Stockholders' equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">895,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,695</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">224,321</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">182,664</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,119,634</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">813,359</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,275,342</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,690,473</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">REVENUE</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 44%; text-align: left">Service fee revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">427,579</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">361,927</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1,247,513</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1,078,265</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Revenue under capitation arrangements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33,563</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,041</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">105,050</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">117,982</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Total service revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">461,142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">401,968</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,352,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,196,247</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Cost of operations, excluding depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">391,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">341,635</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,169,113</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,038,647</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,979</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,822</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,705</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss (gain) on sale and disposal of equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">527</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,183</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss (gain) on contribution of imaging centers into joint venture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,808</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Severance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">304</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,153</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">797</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,157</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">427,231</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">358,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,272,467</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,121,884</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) FROM OPERATIONS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">33,911</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">43,251</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">80,096</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">74,363</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">OTHER INCOME AND EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,776</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,876</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,595</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,084</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,935</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,755</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">949</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Debt restructuring and extinguishment expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,909</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other expenses (income)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,414</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,081</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,248</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,609</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total other (income) expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,320</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,965</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">50,558</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,281</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">INCOME (LOSS) BEFORE INCOME TAXES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">16,591</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">31,286</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">29,538</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">32,082</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,335</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,220</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,927</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,741</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">NET INCOME (LOSS)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">12,256</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">24,066</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">24,611</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">24,341</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net income (loss) attributable to noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,047</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,526</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,163</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">3,209</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">17,540</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(2,552</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">4,904</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.04</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.26</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.08</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.04</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.25</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.08</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">73,494,709</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">67,793,404</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">72,587,321</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">62,113,707</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">75,165,435</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">68,809,818</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">72,587,321</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">63,221,251</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 66%; text-align: left">Net income (loss)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">24,611</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">24,341</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; text-align: left">Adjustments to reconcile net income to net cash provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,822</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,705</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization of operating lease assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,516</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,542</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Equity in earnings of joint ventures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,012</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization deferred financing costs and loan discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,336</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,240</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss (Gain) on sale and disposal of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,183</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Gain on contribution of imaging centers into joint venture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,808</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization of cash flow hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,765</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">949</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,380</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss on impairment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,949</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,974</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,112</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; text-align: left">Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,369</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,379</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,738</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,754</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,388</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,641</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Deferred taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,834</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,389</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,497</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,390</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(255</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Accounts payable, accrued expenses and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57,426</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,091</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash provided by operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">190,494</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">131,943</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Purchase of imaging facilities and other acquisitions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,748</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,915</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Purchase of property and equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(145,164</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(136,537</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from sale of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Equity contributions in existing and purchase of interest in joint ventures</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,496</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,453</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(184,257</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(152,823</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Principal payments on notes and leases payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,296</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,929</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Payments on Term Loan Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(688,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,062</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from issuance of new debt, net of issuing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">863,815</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Contribution from noncontrolling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,569</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Payments on contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,614</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,390</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Distributions paid to noncontrolling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,423</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,523</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from sale of economic interests in majority owned subsidiary, net of taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,641</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,102</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">245,831</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from issuance of common stock upon exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">367</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">400,069</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">231,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(171</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">NET DECREASE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406,346</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">CASH AND CASH EQUIVALENTS, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">342,570</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">127,834</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">CASH AND CASH EQUIVALENTS, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">748,916</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">337,884</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash paid during the period for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51,520</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">59,421</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash paid during the period for income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,202</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RECONCILIATION OF GAAP NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; width: 44%; text-align: left">Net income (loss) attributable to Radnet, Inc. common stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">3,209</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">17,540</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(2,552</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">4,904</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,927</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,741</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,776</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,876</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Severance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">304</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">797</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,157</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,979</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,822</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,705</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Non-cash employee stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,723</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,325</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,381</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Loss (gain) on sale and disposal of equipment and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">527</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,183</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Non-cash change in fair value of interest rate hedge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,755</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">949</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Other expenses (income)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,414</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,081</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,248</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,609</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Non-Capitalized R&amp;D - DeepHealth Cloud OS &amp; Generative AI</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Loss (gain) on contribution of imaging centers into joint venture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,808</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Loss (gain) on extinguishment of debt and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,909</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Non-cash change to contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,276</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,974</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,646</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Acquisition related non-cash intangible adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,950</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,950</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Non-operational rent expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,287</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,030</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,748</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left">Acquisition transaction costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA Including EBITDA from Digital Health</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">73,662</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">57,920</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">204,451</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">166,531</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">EBITDA from Digital Health</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,229</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,279</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,689</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Adjusted EBITDA excluding EBITDA from Digital Health</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">70,433</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">55,641</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">194,433</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">162,842</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PAYMENTS BY PAYOR CLASS</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Third Quarter</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 82%; text-align: left">Commercial Insurance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">57.7%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicare</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22.3%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Capitation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.3%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicaid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.4%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Workers Compensation/Personal Injury</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.2%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other*</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8.2%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: left">* Includes management fee, teleradiology and Digital Health financial reporting unit revenue.</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PAYMENTS BY MODALITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Third Quarter</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Full Year</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 40%">MRI</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">37.1%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">36.8%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">36.8%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">36.0%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.8%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.5%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.2%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>PET/CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.1%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.4%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.8%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.5%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>X-ray</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.1%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.5%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.7%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.9%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Ultrasound</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.7%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.9%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.6%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.7%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mammography</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.2%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.3%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.1%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Nuclear Medicine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.8%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.9%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.7%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.9%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.5%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.6%</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PROCEDURES BY MODALITY*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Third Quarter</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Third Quarter</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%">MRI</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">446,596</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">389,566</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265,874</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,276</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>PET/CT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,844</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,216</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Nuclear Medicine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,533</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Ultrasound</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">650,322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">607,995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Mammography</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">484,357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">452,756</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">X-ray and Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">862,732</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">806,677</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,738,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,511,019</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: left">* Volumes include wholy owned and joint venture centers.</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RADNET, INC. AND SUBSIDIARIES</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE <FONT STYLE="font: normal 700 10pt Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(IN THOUSANDS EXCEPT SHARE DATA)</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023(v)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">COMMON STOCKHOLDERS</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right">3,209</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right">17,540</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Add non-cash impact of cash flow hedges (i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,111</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,260</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Add severance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">304</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Subtract gain on contribution of imaging centers into joint venture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,808</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Add non-operational rent expenses (iii)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,287</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,030</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Non-capitalized R&amp;D - DeepHealth cloud OS &amp; generative AI</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-left: 10pt">Acquisition transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Debt amendment fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Subtract non-cash change to contingent consideration - Heart Lung Health</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">915</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Total adjustments - loss (gain)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,611</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,450</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Subtract tax impact of Adjustments (ii)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,552</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,759</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Tax effected impact of adjustments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,691</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">TOTAL ADJUSTMENT TO NET INCOME ATTRIBUTABLE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">TO RADNET, INC. COMMON SHAREHOLDERS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,059</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,691</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">ADJUSTED NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC.</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,268</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,849</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">COMMON STOCKHOLDERS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">WEIGHTED AVERAGE SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,165,435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,809,818</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">ADJUSTED DILUTED NET INCOME PER SHARE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.13</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">(i)</TD><TD>Impact is the combination of (a) the loss in fair value of the
hedges during the quarter of $6,755&nbsp;&nbsp;in 2024 and loss of $1,015 in 2023 and (b) the amortization of the accumulation of the
changes in fair value out of Other Comprehensive Income that existed prior to the hedges becoming ineffective of $1,356 in 2024 and $1,245
in 2023.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">(ii)</TD><TD>Tax effected using 26.1% blended federal and state effective tax
rate for 2023 and 24.1% for 2023.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">(iii)</TD><TD>Represents rent expense associated with de novo sites under construction
prior to them becoming operational.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">(iv)</TD><TD>Represents pre-tax net income&nbsp;&nbsp;losses before income
taxes from Artificial Intelligence reporting segment.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 20pt; text-align: left">(v)</TD><TD>Restated from what was presented in 2023 to include the losses
of the AI businesses (ie, not add the losses back to earnings as was the case in 2023).&nbsp;&nbsp;The restated Adjusted Earnings for
2023 is due to the fact that AI is no longer its own reportable operating segment and is now embedded in the Digital Health reportable
operating segment.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<U><BR STYLE="clear: both">
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Footnotes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(1)</SUP>
The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations
and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation.
Adjusted EBITDA</FONT> includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling
interests in subsidiaries<FONT STYLE="color: windowtext">, and is adjusted for non-cash or extraordinary and one-time events taken place
during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted EBITDA is reconciled to its nearest comparable
GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare
industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not
be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a
measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented,
may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><SUP>(2)</SUP>
As noted above, the Company defines Free Cash Flow as </FONT>Adjusted EBITDA less total Capital Expenditures (whether completed with cash
or financed) and Cash Interest Expense. <FONT STYLE="color: windowtext">Free Cash Flow is a non-GAAP financial measure. </FONT>The Company
uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity
to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows
generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Free Cash Flow should not be considered a measure
of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives
to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the
consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined
in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable
to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>(3)</SUP> The Company defines Adjusted Earnings
(Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders and excludes losses or gains on the disposal of
equipment, loss on debt extinguishments, bargain purchase gains, severance costs, loss on impairment, loss or gain on swap valuation,
gain on extinguishment of debt, unusual or non-recurring entries that impact the Company&rsquo;s tax provision and any other non-recurring
or unusual transactions recorded during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted Earnings (Loss) Per Share is reconciled
to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per Share is a non-GAAP financial measure used as analytical
indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered
a measure of financial performance under GAAP, and the items excluded from Adjusted Earnings Per Share should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted Earnings Per Share
is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as
presented, may not be comparable to other similarly titled measures of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>radnet_ex9902.htm
<DESCRIPTION>TRANSCRIPT OF CONFERENCE CALL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR STYLE="clear: both">
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O R P O R A T E P A R T I
C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger, </B><I>President, Chief Executive
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper, </B><I>Chief Financial Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O N F E R E N C E C A L L
P A R T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut, </B><I>Jefferies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom, </B><I>Raymond James</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Evan, </B><I>Barclays</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow, </B><I>CJS Securities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Sidoti, </B><I>Sidoti &amp; Co.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>P R E S E N T A T I O N</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good day and welcome to the RadNet Inc. Third
Quarter 2024 Financial Results Conference Call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All participants will be in a listen-only mode.
Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today&rsquo;s presentation,
there will be an opportunity to ask questions. To ask a question, you may press star then one on a touchtone phone. To withdraw your question,
please press star then two. Please note that this event is being recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I would like to turn the conference over to Mark
Stolper, Executive Vice President and CFO of RadNet. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning ladies and gentlemen, and thank you
for joining Dr. Howard Berger and me today to discuss RadNet&rsquo;s third quarter 2024 financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we begin today, we'd like to remind everyone
of the Safe Harbor statement under the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning anticipated future
financial and operating performance, RadNet&rsquo;s ability to continue to grow the business by generating patient referrals and contracts
with radiology practices, recruiting and retaining technologists, receiving third party reimbursement for diagnostic imaging services,
successfully integrating acquired operations, generating revenue and Adjusted EBITDA for the acquired operations as estimated, among others,
are forward-looking statements within the meaning of the Safe Harbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on Management's
current preliminary expectations and are subject to risks and uncertainties which may cause RadNet&rsquo;s actual results to differ materially
from the statements contained herein. These risks and uncertainties include those risks set forth in RadNet&rsquo;s reports filed with
the SEC from time to time, including RadNet's annual report on Form 10-K for the year ended December 31, 2023. Undue reliance should not
be placed on forward-looking statements, especially guidance on future financial performance which speaks only as of the date it is made.
RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances
after the date they were made, or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, I'd like to turn the call over to Dr.
Berger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning everyone, and thank you for joining
us today. On today&rsquo;s call, Mark and I plan to provide you with highlights from our third quarter 2024 results, give you more insight
into factors which affected this performance, and discuss our future strategy. After our prepared remarks, we will open the call to your
questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;d like to thank all of you for your interest
in our Company and for dedicating a portion of your day to participate in our conference call this morning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To begin, I am very pleased with our performance
in the third quarter. It was the strongest quarter in our Company&rsquo;s history with record revenue and Adjusted EBITDA. Relative to
last year&rsquo;s third quarter, total Company revenue increased 14.7% and our digital health revenue increased 34.3%. Imaging center
revenue growth was driven by heavy demand in virtually all of our markets benefiting from the increasing utilization of diagnostic imaging
within healthcare, as well as the continuing shift to procedural volumes away from the more expensive hospital alternatives to ambulatory
freestanding centers like the ones we operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also contributing to the strong revenue performance
was the positive impact of improved reimbursement from our payors, who recognize the important role we are playing as a lower priced alternative
to hospital -based imaging. Lastly, our top line is benefiting from a continuing shift in modality mix towards advanced imaging, MRI,
CT and PET CT, where our revenue per scan is substantially higher than with routine imaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the third quarter, advanced imaging represented
26.7% of our procedural volume, an increase of 142 basis points from last year&rsquo;s same quarter. This is both a function of the overall
industry trend of more of these exams being ordered as a result of technology advances in these modalities, and the significant capital
investments we have made in the last several years in the advanced imaging equipment for growth and replacement. Contributing to the strong
revenue growth within digital health were the AI businesses, including our AI-powered EBCD breast cancer screening program, which grew
75.8% quarter-over-quarter for the past year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusted EBITDA was also a quarterly record. While
the strong revenue results which I just discussed contributed to more EBITDA, our focus on operational efficiency, improved management
and utilization of labor, investments in information technology and effective cost controls contributed to a 27.2% increase from last
year&rsquo;s third quarter. Another contributing factor to Adjusted EBITDA growth was the disproportionate growth in the higher profit
margin digital health businesses. Cumulatively, these factors drove a 156 basis point increase in our Adjusted EBITDA margin as compared
with last year&rsquo;s third quarter. While we are pleased with this margin expansion, I remain convinced we have further opportunity
to improve margins in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The strong operating results in the third quarter
relative to our internal budget resulted in our decision to increase 2024 full-year guidance ranges for revenue, Adjusted EBITDA and free
cash flow, which we also increased after reporting our first and second quarter financial results. Mark will discuss this in more detail
in his prepared remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Twenty twenty-four continues to be a year of investment
in our business. Year to date, we have opened five de novo facilities and we have three additional anticipated site openings for the remainder
of 2024. Moreover, we have 15 additional projects in development which we intend to open during 2025. These de novo facilities are split
almost equally between wholly owned and JV centers and are located in markets where we have patient backlogs, require additional capacity,
or where we currently lack access points to service identified patient populations. While these projects are requiring us to make capital
investments above our normal spending, we are confident that these centers will be material contributors to our long term performance
and growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to grow our hospital and health system
joint venture businesses. Currently, 152 of our 399 centers, or 38.1% are held within health system partnerships, which includes two imaging
centers that were jointly opened in the third quarter with the University of Maryland medical system and one inside our three-way joint
venture in the San Fernando Valley and Los Angeles with Cedars Sinai and the Providence Health system. These and other systems are seeking
long term strategies around outpatient imaging and have recognized that cost effective and efficient freestanding centers will continue
to capture market share from hospitals as payors and patients both migrate their site of care towards lower cost, high quality solutions.
Our hospital and health system partners have been instrumental in increasing our procedural volumes with their physician relationships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to gain momentum with initiatives
inside the digital health segment. Some of you may have seen last week that we announced the first customer for a suite of solutions powered
by the DeepHealth OS. ONRAD, a full service radiology provider to more than 120 hospitals, radiology groups and imaging centers, will
implement a variety of DeepHealth OS solutions to streamline its clinical and operational workflow, including deploying the DeepHealth
OS advanced viewer and smart reporting features. ONRAD, who is a new customer to us, meaning that it does not use any of the legacy eRAD
or DeepHealth solutions, will begin implementation of the DeepHealth OS solutions in the first quarter of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, earlier this morning we announced
a collaboration with GE Healthcare aimed at accelerating the adoption of AI-powered workflows and clinical solutions through smart technologies.
This collaboration brings together GE&rsquo;s healthcare legacy in bringing innovative hardware solutions to our industry with DeepHealth&rsquo;s
leading edge AI-powered digital solutions. Our shared objective is to make imaging hardware more capable, enriching diagnostic equipment
with AI-powered workflow and critical solutions to better service clinicians and patients in all imaging settings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our first offering with GE is in the area of mammography,
where bringing together DeepHealth&rsquo;s SmartMammo solution and GE&rsquo;s Senographe Pristina mammography unit will improve speed,
clinical accuracy, operational efficiency, and improve patient care. SmartMammo is a DeepHealth AI-powered SaaS solution designed to seamlessly
integrate into existing breast cancer diagnostic workflows, enhancing diagnostic accuracy and workflow efficiency. By incorporating imaging
informatics into advanced mammography systems, the SmartMammo solution can support high volume breast center cancer screening programs.
SmartMammo can prioritize cases based on suspicion level and ensure seamless integration and interoperability with existing healthcare
IT infrastructure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As one of its advanced features, integration of
SmartMammo with GE&rsquo;s Senographe Pristina mammography unit will include smart alerts, a workflow solution that alerts rapid AI processing
with the goal of alerting imaging sites to cases with potentially suspicious lesions in minutes. This kind of solution aims to empower
earlier diagnostic examination follow-up compliance and reduced anxiety for women with potentially suspicious findings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The GE-DeepHealth collaboration agreement will
enable GE Healthcare to distribute SmartMammo and other DeepHealth solutions to imaging providers in the United States as part of GE Healthcare&rsquo;s
comprehensive portfolio of imaging technologies. In addition to collaborating on SmartMammo, we and GE Healthcare intend to explore areas
of further collaboration for smart technology solutions in other modalities and clinical domains, expanding the access to and impact of
AI-based workflows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our booth at the RSNA convention in Chicago,
we will be demonstrating, among other things, SmartMammo with a GE Pristina unit, DeepHealth OS workflow solutions, our breast, prostate
and lung AI solutions, as well as other technologies. DeepHealth solutions will also be demonstrated in the booths of GE Healthcare and
Siemens, where we are demonstrating an ultrasound integration with DeepHealth technology. We are meeting with dozens of potential customers
and partners at the convention and through Barclays and Jefferies will be hosting investor presentations at our booth on December 2 and
December 3. We encourage anyone listening today to reach out to Barclays or Jefferies should you want to join one of these investor presentations
at our booth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I&rsquo;d like to turn the call
back over to Mark to discuss some of the highlights of our third quarter 2024 results. When he is finished, I will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Howard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;m now going to briefly review our third
quarter 2024 performance and attempt to highlight what I believe to be some material items. I will also give some further explanation
of certain items in our financial statements, as well as provide some insights into some of the metrics that drove our third quarter performance.
I will also provide an update on 2024 financial guidance levels which were released in conjunction with our 2023 year-end results in March
of this year and revised in May and August in conjunction with our first and second quarter 2024 financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In my discussion today, I will use the term, Adjusted
EBITDA, which is a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and
amortization, and excludes losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, and non-cash
equity compensation. Adjusted EBITDA includes equity and earnings in unconsolidated operations and subtracts allocations of earnings to
non-controlling interests and subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taking place during the
period. A full quantitative reconciliation of Adjusted EBITDA to net income or loss attributable to RadNet Inc.&rsquo;s common shareholders
is included in our earnings release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that said, I&rsquo;d now like to review our
third quarter 2024 results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the third quarter of 2024, RadNet reported
total Company revenue of $461.1 million and Adjusted EBITDA of $73.7 million. Revenue increased $59.2 million or 14.7% and Adjusted EBITDA
increased $15.7 million or 27.2% as compared with the third quarter of 2023. Breaking this performance down to the individual operating
segments, our imaging center segment reported revenue of $452.4 million and Adjusted EBITDA of $70.4 million. This was an increase of
$56.8 million or 14.3% in revenue and an increase of $14.8 million or 26.6% in Adjusted EBITDA as compared with last year&rsquo;s third
quarter. Driving this performance were strong aggregate and same center procedure volumes, the impact of higher reimbursement we are receiving
from commercial and capitated payors, the gradual movement towards advanced imaging, and tight expense control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The digital health segment reported revenue of
$16.4 million and Adjusted EBITDA of $3.2 million. Revenue increased $4.2 million or 34.3% and Adjusted EBITDA increased $950,000 or 41.7%
as compared with the third quarter of 2023. Digital health&rsquo;s significant growth was due in part from a $2.2 million or 75.8% increase
in AI revenue, which climbed to $5.1 million during the third quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total Company net income for the third quarter
of 2024 was $3.2 million as compared with total Company net income of $17.5 million for the third quarter of 2023. Fully diluted net income
per share for the third quarter of 2024 was $0.04 compared with a fully diluted net income per share of $0.25 in the third quarter of
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were a number of unusual or one-time items
impacting the third quarter, including the following: $8.1 million of non-cash loss from interest rate swaps; $304,000 in severance expense
related to cost savings initiatives; $1.3 million expense related to leases for de novo facilities under construction that have yet to
open their operations; $3.3 million of non-capitalized research and development expenses related to the DeepHealth Cloud OS in generative
AI; $417,000 of acquisition transaction costs; and $147,000 loss in conjunction with the extinguishment of debt and related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjusting for the above items, total Company adjusted
earnings were $3.3 million and diluted adjusted earnings per share was $0.18 during the third quarter of 2024. This compares with total
Company adjusted earnings of $8.8 million and diluted adjusted earnings per share of $0.13 during the third quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the third quarter of 2024 as compared with
the prior year&rsquo;s third quarter, MRI volume increased 14.6%, CT volume increased 15.5%, and PET CT volume increased 23.8%. Overall
volume, taking into account routine imaging exams inclusive of X-ray, ultrasound, mammography, and all other exams, increased 9.0% over
the prior year&rsquo;s third quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On a same center basis, including only those centers
which were part of RadNet for both the third quarter of 2024 and 2023, MRI volume increased 9.9%, CT volume increased 9.8%, and PET CT
volume increased 16.8%. Overall same center volume, taking into account routine imaging exams, increased 5.5% over the prior year same
quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the third quarter of 2024, we&rsquo;ve performed
2,738,007 total procedures. The procedures were consistent with our multi-modality approach whereby 73.3% of all the work we did by volume
was from routine imaging. As we now have a table of our aggregate procedure volumes broken down by modality, I won&rsquo;t go through
the numbers but will make the following point. In his remarks, Dr. Berger mentioned that we are experiencing a continuing shift to higher
acuity procedures, or what we call advanced imaging. In the third quarter, 26.7% of our procedures were from MRI, CT and PET CT. In last
year&rsquo;s third quarter, this metric was 25.3%, a shift of 1.4% of our procedure volumes toward advanced imaging. With higher pricing
and better margins, more advanced imaging improves our financial results, including our operating margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overall GAAP interest expense for the third quarter
of 2024 was $19.4 million as compared with $16.1 million during the last year&rsquo;s third quarter. In the third quarter of 2024, cash
interest expense, which includes payments to and from counterparties on interest rate swaps and net interest income earned from our cash
balance, was $4.3 million. This compares with $11.7 million in the third quarter of 2023. The lower cash interest expense this quarter
is primarily the result of a significantly higher interest income on the much larger cash balance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regards to our balance sheet as of September
30, 2024, unadjusted for bond and term loan discounts, we had $261 million of net debt, which is our total debt at par value less our
cash balance. Note that this debt balance includes our 49% ownership portion of New Jersey Imaging Network&rsquo;s debt of $136.9 million,
for which RadNet is neither a borrower nor a guarantor, and it also includes our 49% ownership of NJIN&rsquo;s cash balance of $86.4 million.
This Company-wide net debt compares with $498.3 million of net debt as of September 30 of last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, we were undrawn on our
$282 million revolving line of credit and had a cash balance of $748.9 million. At September 30, 2024, our accounts receivable balance
was $199 million, an increase of $35.4 million from year end 2023. The increase in accounts receivable is primarily the result of increased
business and revenue. Our days sales outstanding, or DSO was at 35.7 days at September 30, 2024, near a historical low.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through September 30, 2024, we had total capital
expenditures net of proceeds from the sale of imaging equipment of $127.5 million. This total includes $6.9 million spent under equipment
notes and the remainder spent in cash, and excludes $15.5 million of New Jersey Imaging Network capital expenditures and a one-time $9
million purchase of software code from a vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I&rsquo;d like to revise and update
our 2024 financial guidance levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the positive trends we are experiencing
in virtually all aspects of our business and the strong financial performance of the first nine months of the year, we are revising upwards
certain guidance levels in anticipation of financial results that we believe will exceed our original and revised expectations. For revenue,
we have increased our guidance range to $1,710,000,000 to $1,760,000,000, which is roughly a $25 million increase to our revenue guidance.
We&rsquo;ve also increased for the imaging center segment our EBITDA guidance by $5 million now to $262 million to $270 million of Adjusted
EBITDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For capital expenditures, we have increased our
guidance level to $145 million to $155 million, which was done in conjunction with increased spending on our de novo facilities, which
we be opening three by the end of this year and 15 locations sometime in 2025. Our cash interest expense we&rsquo;ve decreased to $25
million to $30 million as a result of having a larger cash balance than anticipated and having more interest income. Our free cash flow
guidance range, we&rsquo;ve increased our level to $83 million to $93 million, which is roughly a $10 million to $13 million increase
in our free cash flow guidance. For the digital health segment, our guidance remains substantially the same. We did increase our spend
by $1 million on non-capitalized R&amp;D related to the DeepHealth cloud-based OS and generative AI initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;ll conclude my remarks with an update
on 2025 Medicare reimbursement. As a reminder, Medicare reimbursement represents 22% of our business mix. With respect to Medicare reimbursement
in July of this year, we received a major proposed rate by CPT code, which is typically part of the physician fee schedule proposal that
is released about that time every year. At that time, we completed an initial analysis and compared those rates to 2024 rates. We volume-weighted
our analysis using expected 2025 procedure volumes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As you may recall four years ago, CMS moved forward
with increased reimbursement for evaluation and management CPT codes which favored certain physician (inaudible) that regularly bill for
these services, particularly primary care doctors. CMS proposed doing so at the time with budget neutrality, meaning that as opposed to
reallocating reimbursement from physicians who rarely bill for these E&amp;M codes to physicians who regularly bill for these codes. As
a result, radiology and most other specialties experienced cuts in reimbursement from 2021 through 2024, an intentional phase-in of reimbursement
cuts to pay for the reimbursement benefit provided to the primary care physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cuts we are currently experiencing in 2024
were substantially mitigated by Congressional legislation that was passed in March of this year as part of the consolidated and appropriated
(audio interference). In the proposed (audio interference) in July of this year governing 2025 reimbursement, Medicare will effectively
be phasing in the remainder of the E&amp;M code related cut (inaudible) this year. The cut proposed for 2025 results from a decrease in
the conversion factor in the Medicare fee schedule by about 2.8%, along with certain minor changes to RVUs of certain radiology CPT codes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our initial analysis of the proposal for next
year implies that RadNet on roughly $1.8 billion in revenue would face an approximately $6 million to $8 million revenue hit in 2025 from
its Medicare business. Medicare&rsquo;s final rule, which was released at the very end of October, a few weeks ago, was consistent with
the initial proposal in July. Because the proposed decrease in the conversion factor affects all physicians, not just radiologists, there
have been many lobbying groups from various medical specialties aggressively opposing the cut.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In response to the cuts, Representative Greg Murphy,
a Republican from North Carolina along with seven bipartisan co-sponsors, introduced the Medicare Patient Access and Practice Stabilization
Act. The bill would provide a 4.73% increase to the Medicare fee schedule conversion factor for calendar year 2025, essentially mitigating
the 2.8% final rule that Medicare just released and increasing Medicare reimbursement in 2025 by 1.93%. We expect that this bill will
be put forth for vote in Congress sometime next month, at which time we will have more clarity on 2025 Medicare reimbursement rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;d now like to turn the call back over
to Dr. Berger, who will make some closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is most definitely the most exciting time
I&rsquo;ve seen in our industry. Diagnostic imaging is entering a time of transformation and RadNet seeks to move the industry forward
during this dynamic period. The trends for RadNet and the rest of the outpatient imaging industry are strong and are projected to be sustainable
for years to come. We continue to experience growing procedural volumes driven by advances in equipment, contrast materials, radioactive
isotopes, post-processing software, and more recently artificial intelligence. Patients are more frequently being directed away from hospitals
to more cost effective ambulatory sites of care, like the centers RadNet operates. There is greater focus on using diagnostic imaging
for population health, preventative medicine, and screening programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Most importantly, we are at the beginning of an
acceleration in technology from generative and clinical AI that will transform the way our industry operates and delivers its services.
These advances will increase patient access, improve the patient experience, increase the productivity and accuracy of radiologists, and
most importantly improve patient outcomes. It is our intent to position RadNet to be on the leading edge of this transformation by doing
(inaudible) in our core imaging center business and within our digital health initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inside our core business, we are focusing on growth
areas such as prostate, Alzheimer&rsquo;s and cardiac imaging, which are being enabled by advances in equipment software and radiopharmaceuticals.
We are partnering with health systems to provide patients with better access and lower cost solutions, advancing population health screening
programs for breast, lung, prostate and cardiac disease, and testing alternative site opportunities within Wal-Marts and retail malls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Digital health is making significant progress
with initiatives that are poised to help us drive more revenue, reduce costs, and increase margins. To this end, we are excited about
the commercial launch of DeepHealth OS in a few weeks, which is a delivery platform for solutions that automate office processes and more
effectively manage patient and clinical data, including automating patient scheduling, clinical reporting, medical coding, sales and marketing,
and clinical workflows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In parallel to the DeepHealth OS development,
we continue to grow revenue from clinical AI solutions for breast, lung and prostate cancer screening. Our breast AI is improving the
productivity and accuracy of our radiologists while providing a valuable benefit to our patients, for which they are willing to pay out
of pocket.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are formulating similar screening programs
for prostate, lung and other chronic diseases for both domestic and international markets, as we firmly believe that healthcare needs
to shift towards prevention and early detection and not just focus on treating patients that are already sick.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, as we discussed this morning with the
GE Healthcare announcement, we are also working with imaging equipment manufacturers to bring smart technology solutions to the equipment
marketplace that will greatly benefit all stakeholders: radiologists, technologists, imaging center staff, referring physicians, and patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operator, we are now ready for the question and
answer portion of the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. We will begin the question and answer
session. To ask a question, you may press star, then one on your touchtone telephone. If you are using a speakerphone, we do ask that
you please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw
your question, please press star then two. At this time, we will pause for just a moment to assemble our roster.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our first question today will come from Brian
Tanquilut with Jefferies. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey, good morning, guys, and congrats on the GE
deal and the quarter. Maybe Howard and Mark as well, just on the GE announcement this morning, if you could share with us just more details
on how that contract or that agreement actually works and what exactly does SmartMammo cover? How different is this from your EBCD offering
in terms of what the eventual client/radiology clinics would have access to, or be able to offer in terms of clinical services through
your AI platform? Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, Brian, I hope you&rsquo;re well.
First, let me start by saying that the major component of smart mammography is the embedding of the DeepHealth operating system onto,
in this case, the GE Senographe Pristina mammography system. What that means is that the capabilities of the AI solutions, both clinical
and generative, will be embedded onto the gantry of the GE mammography system, allowing essentially for a turnkey operation. As you are
well aware, we have begun, for example, deploying mammography systems in malls and Wal-Mart locations, and basically this system will
allow us to plug and play. We will be able to install these systems and simply need a power source and a connection to the internet to
essentially make this function in the same way that a patient coming into a RadNet center would experience. In other words, all of the
information systems and clinical tools, which would include the EBCD program as part of our AI clinical package, will be available a part
of an offering that the GE Healthcare system and their marketing and sales force will help distribute for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This will allow more or greater, faster if you
will, deployment of these systems not only perhaps in the more conventional way that people are used to getting their mammography, but
in non-conventional sites where imaging can be performed, like in the Wal-Mart and mall locations. We believe that there&rsquo;s other
opportunities for distribution of this type of network of equipment that will help facilitate access and compliance and make what is estimated
to be about a third of the female population more accessible to getting early breast cancer screening.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think the best way to look at this is it&rsquo;s
a collaboration between, in this case, GE with their mammography system and RadNet with their DeepHealth AI tools to essentially create
an environment that will allow not only easy access but also facilitate the results and distribution of information, since the DeepHealth
system is a cloud-native based system. Things like faster turnaround time for the reporting results and to the patient will allow us more
rapid opportunities to navigate people into the next appropriate step for their mammography or breast screening programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Did I leave something out there, Brian, that you&rsquo;d
like me to elaborate on further?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No, that&rsquo;s really helpful, Howard. Then
maybe just one comment that you made earlier, that you see opportunity to drive margins further up. Just curious how you&rsquo;re thinking
about the composition or the drivers of that. Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The improving of margins is really where we expect
the DeepHealth operating system, which we have already begun to deploy some of the modules inside RadNet centers, will streamline activities
which are manual processes right now relative to things like scheduling, reporting tools, data migration to the cloud, (inaudible) medical
records, revenue cycle management, coding&mdash;I could go on and on. But things that are both currently dependent on a limited labor
force to try to help keep up with the demands that we have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What we&rsquo;d expect to do is be able to process
a lot more in the way of our patient demands and needs that will be not only faster but even more accurate, and make all of our employees
that much more efficient in their use of these systems. I think the response of the DeepHealth platform is one to which is an existential
problem that everybody in healthcare has, but particularly in radiology with the shortage of both radiologists, technological staff and
office staff to help facilitate the patient experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All right, got it. Thank you, Howard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks Brian.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our next question today will come from John Ransom
with Raymond James. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey, good morning. Just want to unpack this GE
deal a little bit. Who are your primary targets for selling the solution to, and who&rsquo;s going to be responsible for that selling?
Is it going to be yourself, is it going to be GE? Should we think about maybe Wal-Mart being one of the top potential suspects in terms
of getting this rolled out?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The prospects for this are obviously current hospitals
and imaging center outpatient or ambulatory imaging center providers, but I think there&rsquo;s a bigger market beyond that in what we
like to refer to as alternative or non-traditional imaging locations, much like what Wal-Mart and the retail malls that we are experiencing
and piloting for this kind of access. When you stop to think of what that market could look like, it&rsquo;s substantially larger than
just the existing conventional market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we think that there&rsquo;s other
market opportunities. There are companies out there, and we&rsquo;ll be one of them, that will be looking at providing mammography in
OBGYN offices, where women come for their wellness visits on an annual basis and for which that market is already being tapped into, and
which this is a particularly good opportunity. Given that, as I mentioned just a moment ago, this is a turnkey operation that will allow
RadNet to install these with just the need for a power source and a connection to the internet in order to provide not only the equipment
and doing the mammogram itself, but registering patients, billing for patients, facilitating the storage of medical records and retrieval,
doing the actual interpretation by using clinical AI such as the Saige-Dx program, access to the EBCD program, and all being able to do
this with a goal of trying to give results to a woman while they&rsquo;re still in the office. These are the kinds of transformative changes,
I think that the technology will allow us to achieve while doing a better job of compliance and access for early detection, and ultimately
get better outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This will be a dual role for both GE and RadNet
to help. First the RadNet team through the DeepHealth division, try and enable and educate the GE marketing and sales force, which is
quite extensive not only here in the U.S. but globally too, where these kinds of products will even be more embraced for large scale screening
programs. I look at this as truly being a collaboration not just in terms of creating the product and deploying it, but educating and
giving a greater opportunity for making this type of inroads as quickly as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will of course, meaning RadNet, will look to
sell the DeepHealth platform, which is something that can be integrated with other mammography systems, but none that will have what the
current integration between the GE Pristina mammography system and the DeepHealth, to be embedded and fully integrated so that there is
not a variety of AI and IT tools that all have different vendors and require far more cost, as well as difficulty in implementing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Then just switching gears - Mark, I know
we&rsquo;re not giving &rsquo;25 guidance today, but I know you talked about the Medicare headwind, you&rsquo;ve talked about the de novos.
What are some of the other puts and takes we should think about when we build out our &rsquo;25 models?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure, and obviously we issue guidance&mdash;we
will issue 2025 guidance at the end of February of next year, and we&rsquo;re going through our budgeting process today, so I don&rsquo;t
want to go too deep into it. But I will say, as you mentioned, the headwinds are potentially on Medicare side that could be a much as
a $6 million to $8 million headwind should the final rule go into effect as proposed. But we do think, and our experts think, that that
will be either partially mitigated or fully mitigated with this Congressional bill that I talked about in my prepared remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The other challenge I think that we&rsquo;re facing,
like every other healthcare company within radiology and outside of radiology, is the increasing cost and availability of labor. We&rsquo;ve
been managing through that as best we can. We&rsquo;ve certainly&mdash;it&rsquo;s been inflationary as we&rsquo;ve had to pay more to
attract talent and to retain talent, but on the positives, the business continues to experience heavy demand. We have backlogs in virtually
every market in which we operate. We are in the process, as we mentioned, of building new facilities aggressively to build our capacity,
to meet the heavy demand that we know exists out there. We&rsquo;ve got three centers that we&rsquo;re anticipating opening before year
end. We&rsquo;ve got 15 de novo projects on the docket for 2025, and we&rsquo;ll have additional projects after 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ve also&mdash;we&rsquo;re aggressively
expanding our hospital joint ventures, as we said in the prepared remarks. We had three additional sites that went into joint ventures
in the third quarter, two within the University of Maryland system, one here in Los Angeles with Cedars and the Providence Health system.
We&rsquo;re going to be announcing new relationships with new partners. We&rsquo;ll have new joint ventures with existing partners and
expansions with our joint venture, so that will be built into next year&rsquo;s budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;re also experiencing, as we noted in
our prepared remarks, a shift towards advanced imaging modalities. We had over a 140 basis point shift in this third quarter relative
to last year&rsquo;s third quarter in favor of MRI, CT and PET CT. That comes with higher revenue, higher margins and profitability. We
don&rsquo;t see a&mdash;we think that that trend is sustainable going forward, not because we&rsquo;re driving it, although we are aggressively
investing in this technology in terms of our growth CapEx and our replacement CapEx. But that&rsquo;s just what&rsquo;s going on in the
industry with all the technology advances around the equipment itself, post-processing software, contrast materials, radioactive isotopes.
It&rsquo;s driving more indications for physicians to order these types of diagnostic tests, so we think that that trend will be positive
for our guidance next year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ll continue to be doing some small tuck-in
acquisitions. We&rsquo;ve got an active pipeline today as we speak, and that will continue to be a part of the strategy going forward.
Of course, all of the growth that we see within digital health, not just this GE SmartMammo announcement but the continuing growth and
penetration of our EBCD program, further growth in the U.K. and in Europe with our lung AI product, the DeepHealth lung product where
we&rsquo;re rolling out a program in the U.K. called the targeted lung health check program with the National Health Service there that
will continue to drive revenue. As many investors will see at the RSNA in few weeks, that we&rsquo;re going to be working in other areas
with other modalities, other equipment manufacturers around embedding smart technology tools and solutions into other equipment and other
ultimately alternative imaging locations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think we&rsquo;re excited about the next 12
months, and most importantly we&rsquo;re coming out with the DeepHealth OS commercialized product, which we have to start marketing and
selling aggressively within 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Just lastly from me, the structure of your deal
with GE, is this a software license? Just how does that work?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi John, it&rsquo;s Dr. Berger again. Yes, this
is a software licensing arrangement with GE, and they will through their sales and marketing force distribute that for us on their equipment.
We will, of course as I said, also be doing some of that ourselves directly to other providers and in other opportunities, where the benefits
of our DeepHealth program. It is a licensing product or program right now which has the capability of also being SaaS-based. We&rsquo;re
playing with all of the models because some people might want to do this more as a capital investment, some people might want to do it
as a variable expense. We&rsquo;re capable of doing that because we not only put the clinical AI tools on there, like the EBCD program
and reporting tools, but also the office-based generative AI tools, which are the radiology products that manage the rest of the other
office requirements, like scheduling and billing in a turnkey operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Ransom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, John.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our next question today will come from Andrew
Mok with Barclays. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Evan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, good morning, this is Evan on for Andrew.
During the quarter, we saw AI revenue decrease nearly 10% sequentially versus 2Q, while mammography volumes remained largely constant.
What were the underlying drivers of that, and do you still expect the AI business to exit the year profitable? Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, thank you for the question. Yes, it was a
little&mdash;I guess I should have pointed this out in the script, in Q2 we had a $600,000 implementation fee within our AI businesses
that was not recurring in 2023. If you adjust for that, the AI business went up sequentially, I think, $100,000 to $200,000. I probably
should have called that out. The answer to the second part of your question is yes, we do still anticipate that the AI business will reach
profitability here in the fourth quarter and entering into 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Evan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Just a quick follow-up, what is the current EBCD
adoption rate on both the east and west coast? Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, the adoption rate on the east coast, where
it&rsquo;s now been implemented for approaching two years, is approaching 45%. Our goal is to get it at 50%, and there seems to be good
trends that make us confident that we can get there in 2025. On the west coast, the adoption rate is closer to 30%, but that&rsquo;s weighed
down somewhat because of the large capitation program that we have here, and for which we are negotiating with all of the capitated providers
to have the EBCD program become part of their capitation by providing us higher revenue. We expect to have progress that we can talk about
that in 2025 also. If you were to strip away the capitation portion of our business, our adoption rate here on the west coast, where it&rsquo;s
only been implemented now for a little over a year, would probably be closer to 40%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Evan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks for the color.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our next question today will come from Larry Solow
with CJS Securities . Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thanks, and good morning, Howard and good
morning, Mark. I guess just following up on the digital health question, just on the GE collaboration, just any timelines on when&mdash;I
guess they&rsquo;re rolling in your software into an existing machine, right, so take that usual OEM length of time, but could you just
give us an idea of when these products actually will be available for commercialization?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;ll answer that one, Larry, good morning.
The commercialization efforts will begin really at the RSNA, where we will have the SmartMammo both at our booth and the GE booth at McCormick
Place, where the meeting is held in Chicago, on demonstration, and which we are able to deliver today. There are some upgrades that are
coming to the GE system that will further enhance the viewing and resolution that are in for FDA approval, that hopefully will be an upgrade
to the systems that they may sell today, sometime in the second quarter of next year. But essentially, the tools are tested and pending
a final FDA approval that DeepHealth will be getting about adoption or application of the EBCD&mdash;excuse me, not the EBCD but the AI
tool in the GE systems, which we expect this month, will be ready for a rollout of these systems in the first quarter of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Got you, and then just&mdash;Howard, just give
us an update just on your efforts to build out both on the hospital partnership side and on the collaborations with large healthcare institutions,
and also just acquisitions, maybe an update on how Houston is coming along. Obviously, you made a couple of nice-sized tuck-in acquisitions
there to build out, start building out a new location. Just maybe give us a little update on those elements there. Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think Larry, as Mark mentioned, we have an active
pipeline of acquisition opportunities, both small and large, that we&rsquo;re considering. As you are well aware, we have a rather substantial
cash balance and are looking to deploy that capital both on the DeepHealth side as well as on the imaging services side. We&rsquo;ve got
15 more de novo centers which are in various stages of construction that will open throughout the course of 2025 as well as three more
that will be operational in this quarter. We are deploying our capital in every aspect that we can to drive more revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we&rsquo;re also going to see opportunities
that may drive opportunities in the AI space, where we may have critical AI tools that we may feel that we can acquire in a very attractive
manner, rather than build ourselves. While the AI tools that we have today are primarily screening tools, cancer screening tools for breast,
lung and prostate, there are other work efficiency tools and improvement in diagnostic accuracy in other areas of our business for more
of the routine work that we do, for example in ultrasound and in X-ray, that we will be looking for, that will help drive productivity
and accuracy for our radiologists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think that is a pretty big&mdash;there are a
lot of things on the plate for us to look at in 2025. Along with increasing the number and breadth of joint ventures&mdash;centers that
are in joint ventures with hospital systems, that I believe once we&mdash;they become more aware of what the DeepHealth and smart technologies
allow us to do, will make them even more excited about driving their relationships and partnerships with RadNet further into their hospital
systems, even if it&rsquo;s not with centers that we currently enjoy in a partnership arrangement with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Larry Solow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thank you. I appreciate all that color.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our next question today will come from Jim Sidoti
with Sidoti &amp; Co. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Sidoti</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hi, good morning, and thanks again for taking
the questions. You talked about the program in the U.K. for screening for lung cancer. What are the hurdles you need to implement that
in the U.S.?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That&rsquo;s a question, Jim, that unfortunately
doesn&rsquo;t have a great answer right now . Part of the problem here in the U.S., as opposed to, let&rsquo;s say the U.K., the U.K.,
I think as most people know, has a national health service, the NHS, that manages over 90% of the healthcare for the population. Therefore,
once they adopt something, it&rsquo;s a lot easier for them to push it down. We really don&rsquo;t have a similar model here, and even
though lung cancer in the U.K. has already been determined to be of extraordinary value in terms of better outcomes, for those people
who are at risk, which right now the United States public service task force has said is 50 years of age and 20 years of smoking history.
Still, only about less than 5% of the patients eligible are accessing it. To be perfectly blunt, it&rsquo;s the hurdles that are placed
in front of patients who are at risk; they have to go through a consultation, they have to get authorization, and there&rsquo;s a substantially
different problem than what women face when they&rsquo;re at risk. One out of every eight women will experience breast cancer in their
lifetime, and they can self-refer. There is no such thing as self-referral for lung cancer, and I believe there is more and more advocates
that are recognizing this as a hurdle.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What&rsquo;s happened in the U.K. is that the
patients can now go directly to an appropriate provider in the U.K. and get their lung screening without having to get an authorization
or a consultation. Somewhere, sometime, something similar to that has to be adopted here if we&rsquo;re truly going to get the number
of people who should be scanned into the system. I think this is something that&rsquo;s tantamount to almost a type of epidemic here,
where people who would qualify and get their lung screening at an earlier stage (audio interference) their outcomes if there a lot of
these screening tools available. The very things that we&rsquo;ve put together and continue to put together, like access and compliance,
are what needs to be revamped here in the U.S. The expectation is with the efforts that we see that the NHS is making in the U.K., within
another two years, perhaps 80% or more of the at-risk patients there will be getting annual lung screening, annual or biannual lung screening.
This is a case where a socialized healthcare program certainly has achieved a lot better results than we can here, or we have here, despite
having all the technological skills to do something which can certainly provide better outcomes for patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think having said that, right, the idea
here is to be&mdash;is to use these models, like in the U.K., to talk to the payors here about widespread population health screening
for lung cancer. We are in the process of getting FDA approval on the Aidence lung&mdash;or the DeepHealth Aidence lung product here,
which we&rsquo;re anticipating receiving sometime midyear 2025. We&rsquo;ll have the tools, as Dr. Berger said, to be able to launch similar
programs here, and obviously we&rsquo;re going to share the success of the U.K. with the payors and see if we can get some traction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Sidoti</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the new administration coming in, in general,
not just lung cancer, but in general do you see any new risks for your business, any new opportunities for your business, and how do you
think you&rsquo;ll adapt?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I&rsquo;m not sure the new administration
coming in really impacts our business in a big way. I think when we were under the Trump administration from 2016 to 2020, they were supportive
of a lot of the programs that the current administration has been pushing; you know, cancer programs, cancer (inaudible). We&rsquo;ll
see, I don&rsquo;t know&mdash;you know, reimbursement might change. Howard, what&rsquo;s your perspective?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think there&rsquo;s one area where we may, and
healthcare in general benefit from the new administration, and that is regulatory issues. Right now, there is a substantial hurdle that
any growth, and particularly with mergers and acquisitions, has to pass in order to do sizeable acquisitions. My strong belief is that
those burdens will be lower and make, I think, available what needs to continue in healthcare, and that is creating scale for businesses
that can deliver cost effective healthcare. If it&rsquo;s one area that I think we can point to that I believe does need some changes,
if you will, are regulatory, and that seems to be a major effort that the Trump administration will be focusing on.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Jim Sidoti</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right, thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This concludes our question and answer session.
I would like to turn the conference back over to Dr. Berger for any closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Again, I would like to take this opportunity to
thank all of our shareholders for their continued support and the employees of RadNet for their dedication and hard work. Management will
continue to endeavor to be a market leader that provides great services with an appropriate return on investment for all stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you all for your time today and sharing
this important and exciting journey with us. I look forward to our next call. Good day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The conference has now concluded. Thank you for
attending today&rsquo;s presentation. You may now disconnect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #B @\# 2(  A$! Q$!_\0
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M/!7@I/ NG?88;R]NK&,@6Z7,AEDMU'1 Y^9@. -V6XY)ZUOT %%%% !1110
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MZ+ZG^M>N_#OX,Q^+-3^U7BG[#"V2,?ZT^G^)KVN&.'3+)458X88$& /E5 *
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M<\-:M9ZQI=XH:*>VD#J?8^A]0:\A^//_  2\^!W[0ADFUCP#HMGJDF2NH:9
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M8/\ A]I_B;QY>7-GIVIWRZ=;B"$S2/*4=\8';:C<U\TK_P ''_[.)_YBFO\
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M&\2VCJI^5[Z4*\Q/;*J43V*M7T[_ ,$H/@&OBBZ;7[Z'=I^CX"!AQ+,>0/\
M@(Y/X5^5OP6\0WWQE^+6M>+-2W2:AXFU6?4K@YR?,FE9R/UP/;%?T&?L=?"9
M/@Y^SWX;TDQB.[DMENKO Y,L@W$'Z @?A0!Z@B[% ]*=110 4C_</TI:1_N'
MZ4 ?S3?\%^/^4J7Q(_W=/_\ 2&"OCNU&+M/K7V)_P7X_Y2I?$C_=T_\ ](8*
M^.[4_P"EK]:_*8_\CC_M_P#5']F?\T1_W+_^VH_J8\)_LS^#?VF?V%? WAOQ
MAH.GZO8:AX/TZ$F6)3+#FTC^9'QE6!P017\V/[9_[.MU^R=^U#XV^'UT[2_\
M(WJ+V]O*PP9H&P\+GZQLAK^H[]E _P#&+'PUSW\*Z9_Z215^!'_!Q7HL.D_\
M%0/%$T.-VH:5IUS*!_?\@)_Z"BU]-Q=AJ?L(UDM4[7]3\C\#\VQ"S*>!<FX2
MBW9[)II77;1ZGQW\)/'M]\+/B9H7B339&AO]#OH;^WD4X*O%(KK^97\C7]<W
MP_\ %<7CKP/H^L0_ZG5K&"]0_P"S+&''Z&OX_+$_Z2M?UF?L3O--^R!\+6N,
M^<WA/2]^?7[)'71PE5E+ \LNDFE^#/-\:L-"EGZG#>4$WZIM'J&0!Q39V&P_
M2G9!6J'B358= T*\O;A_+ALX'FD8]%51N)_(5].]%=GY'&+DU&.Y_-[_ ,%^
M/C&/BY_P4Q\9QQR>;:^%8+;0H>>%\N/?)^4DCBOBZNT_:+^)<GQE^/GC+Q9)
M(96\1:U=ZB&/7;+,S+_XZ17'SQM$J$K\K <U^.8M3KU:N(6U]?F[(_NK(?8Y
M=@L)EDM)."27=J-V?J%_P:X?&%O#/[4OC3P;),J6_BC0!=QH3]^>UD&,?]LY
M9#^%?NYT%?R]_P#!'3XP?\*5_P""C?PKU1Y/*M[S64TFX)/R[+M3;G/L#*#^
M%?U";LU^HY-B/;8*G/RM]VA_(?'V6_4L_P 31MHY.2]):_J*3\PJMK7_ "#+
MC_KDW\JLG[PJMK7_ "#+C_KDW\J]&6Q\G1^->I_'GXE_Y#][_P!=W_\ 0C7O
MG_!)<;O^"C_P9!Z?\)79?^C!7@?B7_D/WG_7>3_T(U[Y_P $E_\ E)!\&?\
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M#1#IR.V/2NH\&>-])^(?AVVU;0]2LM6TV[4-%=6LHEBD'L10!L4444 %%%%
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M'_HA:M?"S.3?,EZGHG_!8/\ :)\:_!'XB^#[7PKXBU#18+[3II)TMWVK*RR
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M?PQ>:1I64ZI$"QZ*NJ7:J/P4 ?A7SC_P6J^*5QXI_:4T_P -+)_H/AG38V*
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M;KA?K7V-_P %^/\ E*E\2/\ =T__ -(8*^.;/_CY3ZU^4Q_Y'"_Q_JC^S/\
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M._\ )%]4_P!Z'_T:E?T.?LH_\FQ?#O\ [%K3O_26.OYX_P!IW_DB^J?[T/\
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M\ZCS(V]"5/S*17M6: ,W0->35[90W[NZ11YL).&0UI9K@OC3\.-2\3:3]O\
M#MXVF^(;,;K>53A9?]A_4&OGK0_^"HEE\)O&#>%_BYI-UX;U&!MC7Z1$PMC^
M-EZX/JN10!]A9I'^X?I7-?#7XO>&?B_H*ZEX9U[2M<LW /FV=PL@3/9@"2I]
MC@UTCM\K?2@#^:7_ (+[<?\ !5#XD9_NZ?\ ^D,%?'EI_P ?4?UK],/^"S'_
M  3F^-GQY_X*)^.O%/A'X>:YKF@ZFME]GO+?R_+FV6<2-C+ \,I'2OF33/\
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MZC@=Q7[*L/Y5=3H9T^OJ?!O_  7;/_%M_ /_ &$[C_T4M?FC)]PU^K'_  6
M^!/B[XY>!_!EMX3T.\UJXT_4)YKA8,9C5HU4$Y([U\&_\.^?C-_T(.L?^0__
M (JH-#H/^"8_[<<7_!/;X+:YX3FT*3Q$^L:[-K(N$G\CR_,CC39C!Z>7USWK
MZ3_X?M6W_0@S?^!X_P#B:^3?^'?'QF_Z$/6/_'/\:3_AWS\9O^A!UC_R'_\
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M10 ;?:F^6OI3J* &K$%%.(R*** &^4*/*%.HH ;Y0H5-M.HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH #TK\R?^"XWQ;&L?$SPKX-AF
M/DZ+9/J-TH/ EF.U0?=8TS_P.OTU89-?DQ_P4R_8*^._Q8^,7B_Q%H?AM-<'
MB2Z6WL);*\0BT@^2&-G#E2"L8W'&><]:/(+V5SJ/^#?7]GUO$.I^./CAJ4.5
MU27_ (1KPXSCI:0-F>5#Z22X&<?\LS7Z?,W&*\__ &6O@+IW[,'[/GA+P'I,
M:K:>&=.BM"ZC'GR 9DD/N[EF/^]7H"CBJD[DQC9#3;1G^%?RIR($7 7 IU%2
M41M"KG<5!/09'2@0JG*J,^N*DHH :Z;QAN1TQZTT6R _=7\NE244 -5=J^WI
M3J** *MWH]KJ!_?V\,WH9$#8_.H[7P[8V4WF0V=K#)_?6)0WYXJ]10!%)")5
MPPW9X(Q^=+%"(4VJH4=L# %244 %%%% &9XF\+V'C'P_?:5J=E!?:=J4+VUU
M;3H'CGB=2K(P/!4J2,'L37\QW_!5_P#X)]^.?^"%/[<^@_%CX927D7P_O-6&
MI^&M00%ETBX!WOITY_NX+!<_?C)')#5_4)7G7[4G[+W@[]L3X'Z]\/?'FDPZ
MSX<\00&&>-QB2)NJ2QMC*2(V&5AR"* .(_X)Q?MW^%_^"BO[+'A[XC^&Y(HY
M+Z(0ZKIX?,FE7R@>="WX\J3]Y64]\5[YG-?SC_!K5OB7_P &MG_!1PZ#XP;4
M/$'[/GQ$N!!_:L<1,-S!G"7  X2[MPV'3^),XR""O]#W@+QWH_Q/\':7X@T#
M4+75M%UBUCO+*\MI!)#=0NH975@>00: -JBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I"H(I:* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /*?VQOV-/ /[=OP+U;X>_$718=8T'5DX;
M[MQ92C[D\,G6.1&Y!'7H<J2#^8W[%'Q,^(?_  ;]?'^U^ ?QMU*Y\0?LZ^,;
MYHO 7CUU/D:)<NQ/V2Z/2%6)Y4X4-EE^4OM_8^N-^.WP&\(_M+?"[5O!OCG0
M-/\ $GAO6H3#=V5W$'60'H1W5@0"&!!4@$$$"@#K+*^BU"W2:&1)8I%#*Z-N
M5@>001V-35\7_L]>'?&W_!,#5+?P#XDU/4O'/P"9A#X8\37),VI^"%)PEAJ.
M.9;,=(KH#,>-LF%VL/LRWN4NH5DC=)(Y%#HRG*LIY!![CWH DHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** (;FTAO8GAFBCFAD4J\;J&
M5QP,$'@BN&_9YMX[/P5=VL,:16MEJ5U;V\*+MC@C1\(B*.%51T X%%% '?T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" ($ LL# 2(  A$! Q$!_\0
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M (;*\(_\\]8_\!U_^+KPD_ [5A_R\:?_ -_'_P#B:3_A2.J_\_&G_P#?Q_\
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M^'_G1[[_ ,-E>$?^>>L?^ Z__%T?\-E>$?\ GGK'_@.O_P 77@7_  I[4_\
MGO8_]]O_ /$TG_"H=2_Y[V/_ 'VW_P 33^K5>POK^'_G1[]_PV5X1_YYZQ_X
M#K_\71_PV5X1_P">>L?^ Z__ !=?/Y^$FI+_ ,MK+_OMO_B:3_A5&H_\]K+_
M +[;_P")H^JU?Y0_M##?SH^@?^&RO"/_ #SUC_P'7_XNC_ALKPC_ ,\]8_\
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M!4?_ *.FJS^SE_R)%U_U_/\ ^BXZK?MK?\E4L/\ L%1_^CIJL_LY?\B1=?\
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M7MNEQ!+M(8;D<%3@@$9'4"J7@CX7^&OAE!<1^&_#NA^'X[M@\Z:;816BS$9
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MW,!@GNQ.3G!!/;:NX/"W24-6S[/(Q45[<165K)//)'##"ADDDD8*B*!DDD\
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M]>#?V1O%.N?M ^'/B%X]\0^&;S4?"D<ZV<.@:)]A:\DEC\LR7,S.SN I.$X
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MHKLM,9<599,U$R;:HAH@9*^SJ^-63-?95>+F_P!CY_H?5\+?\O?^W?U/E_\
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M&_AO0/#&@SI%YOER2!96$BO$K[8T=G:-V9I=H*K&HK]F@V:_'CQK\)_VF?\
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M^)OV[_\ @I;\"?$>AB4? 3PG\4['PKX4O%?$/B+4K>]LWO[Y!_&G[R)$?IL
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MO$4=SX7U#QGX-6ZL;Q6N;LR264MU"8W!7RRS1$Y&S/:OH_\ X*T_LMV6B?\
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M 7CWXI_$3]A^X\*^"O%WB.+PEXVM+O6Y-*T>XO%T6%9=-)EN3&C>2@\MSN?
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MK;>,-0NAI^O:5/IMT8FAM0LGE3*K["58!L8.T^E.'-*2;\PJQA&$E'R/F/\
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M0?&W4KZ'7=&TRUABM/W-O)%)':7;QL81<2 38*[50O$&((8CQG]KOQ/\?/\
M@J7^Q1X _9=T_P#9F^*OP\\6VUWI-OXL\4>*-.^Q^%],CLDV//:W6X_:59@'
MPHR%RJ^82#2<FMBHPA+XK/77R]#[$_;P_P""Q-Q^QC^VS\,_@SI7PEUGXF7O
MQ-T=M1L+C1=72.Z\XM.D4"6[Q%'5GA7=*T\:QH[.>$.<[]E;_@L5XL_:$^-W
MQB^#>M_ +6/!'QX^%OANX\1V?@^?Q5:WEOKZK'"8(!J"QK# \KW5JH<AXPLV
M_<0K >4_M4_LL^,]-_X+Q?L=:OH7A+Q?K?@;P%X/DTG4?$<&D3S:=8-'#J$:
M"XN$0Q1.VZ/AF'WUQU%:WPQ^!'CG3?\ @Y[^(WCZ;P;XL@\!W_PXAL;?Q&^D
MW"Z1<7 BTX&%+HIY+29C?Y0V<HW'!IWE?YD<E-1VZ7_$^+O^",_B5O''[:_Q
MO_:3^,OPLO[Q/ /B#6-7UCX@W?CTNOP[\NVNG;35TY6W:@I#>4C*&5-D>Q1C
MG[2TW_@X1U72O"'AGXH>,_V</''@W]G/QCJB:9I?Q"GUVTN9U$CLD=Q<:8B^
M;#"2K'?YC @?)O) /CG_  3@_P""?_Q(^)'[#_[=/PWUSPMXC\#:Q\3?$^I_
M\(Y)XATJXTZ+4"R2-!*AE0;X&D" R(& #$C/2OEWX.?\$R&\3?#3X?\ PMC_
M &"_%L/QVAU9;#QCXU\;7NNQ^"EL SA[Z*>SU.WCDEP4;RXCMPC!/,+*!FG-
M)6.B7LYR?-T_*WJ?J!^W9_P6>U+]D#]OOP)\!/#OP=U#XH:S\0O#*:YI-SIO
MB**SDFN99+Z*"V$4D)C\MGLT+SM,JQI*SE3Y>'D^+G_!8'Q=\*)/AA\/S\ -
M;UC]I;XEV=SJ*_#&R\4VC)HEK#-/&)[G5"@A5)$@=U8)M^5P2, MY1^T%^R]
MXL/_  <L_LQ>*-+\"^*+_P"&_A#X:2Z5=^((M(NKC1]-FCM_$"Q12W9#1I(#
M);X$DF_,L?)+ G@_^"X'_!.N^\;_ /!27X<_'+Q!\%O&'[0'P;_X1W_A'O%7
MAGPG)/\ VU9S1-<M#/'';RQS2+F=& 5@I,+J[+O7-MSU?F81ITKQ3[7^?WGU
ME^S3_P %>+/XZ?#/XV#7OAWK/@#XL? /3;B_\4>!]3U&.8CR[:2>,PWD:%)(
MI/+*^8(^,JVTJREOG/1_^#D?QCKO['-I\=[7]E+Q9-\--/O_ +!XFUH>+[5+
M;27:Z$"?9@\"S7@.^+<PBCC61_++Y4FL;_@G7^PG=^"OV?/VI_&VB?LWGX&Z
M7XR\):IX?\#Z#/<:U=^+=8LVMIF!OK>ZOKB-)6?R52..%)-QD'*[2_.?!C]F
M'XE:7_P:F>*/AW<_#SQS;_$"X2]$7AB70;I-9EW:ZLJ[;0Q^<<Q_.,+RO/3F
MES3:^0_9TK[=4OOWZGVE^UW_ ,%@_!?[-/[.OPB\9Z/X<\0>//$7Q\BLW\ >
M%;';;WVMM=0P2IO9@1$!]IMU8X8AID 4Y)%']C;_ (*S7?QM_:;\0_!/XN_"
MK4_@1\5]#T?_ (2&+2K_ %VVUBRU#3^-TL5Y$J(64-N*@$85_FRC ?'/QU_8
MD^+^B_LH_L ?&3PO\/O$7BCQ'^SCIVGOXH\$?9VM];DM]MG(ZQ02 .)D-M(A
MCVE\R(=F%:OK']G_ /:G^//_  4'^-WBK1YO@UK?P:_9[E\,SZ?->^/]!GT[
MQ??ZE-&\>+>#[1Y:PKO#$M&P(C/SYD 2U.5S-TX*&GGK?S/--4_X.$-4U7P;
MXC^*7@[]G'QSXO\ V<O"6IMINI?$*+7+2UG<(ZH\]OIDB^;-""R_/YB@ _/L
M(8#]"?A5\3M$^-?PR\/^,/#=ZFH^'_%&G0:KIMTH($]O/&LD;8/()5AD'D'@
M\U_.]\.?^"76I? OX/\ B#X6^+?V&/'/Q1_:$BUTV_A_QC]OU8>!M0LFE3][
M<W-I?6T406,/M&5)W(9&0AEK]_OV3?@JG[.?[,_@7P,EGI.GGPOHMM826VEO
M=/8P2K&/,6 W4LT_E!]VSS97;;C+&G2<Y?$&)A3BER?U^+_0_+C]I#X?>+_^
M"W__  5X^*'P(U?XB>)? ?P.^!^FP)?Z7H4PCN-?NI5C#L^X%"3([@-(LBHD
M*A4S(S5[;^P;_P $2_'?_!-#]LBUU?X7_&W6;SX#W-DZZOX/\1YNKF[G97&5
M$2QVZLK>7(LZHK_>0JRDEO//VMO@9^T)_P $R?\ @I[XS_:6^"'PUF^-?@'X
ML:?%%XL\+:>S#4[.>)(P3$$5Y?F:,2*Z1R_ZR5&0?(Q]"_8<_;)_;5_;:_;'
MTK6/$'P8'P%^ ^G6;IJ^F>*;.1]4OIAOVF!I8X)_,9B@SY2Q*B,3N8J#$;*7
MO+6Y<G+D]QKEMY?U<ZC]M#_@L/\ $#]F7QYXUM_#W[,_BKQ%X-^'J%M6\6^)
MO$MKX,T^^VJ6D.FB]C)U!5VL,P9)(& 0Z,WRK_P73_;2\/\ _!07_@@-X+^*
MWAJQU#2M.\1>-;-'L;T#SK*>$7T,L99?E8!T;##[RD' .5'FGQ%_9%^(T_[8
M/[4T'Q8_9?\ B7\>_B)X_N[NW^%?BHV_VGPQH=K*;I8'DN99%MK=8XY+9E4A
MF4P; (R2QS/B!^R;\6M>_P"#8SP/\.[;X4?$]_'NB_$:2:[\.GPI?C5(X6EO
MI1.+8Q>:8=LT?[P+MR<9R"*4IRDFBX4J<7&2WNOZW_R/HG]KL8_X.&OV(?\
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M2X0/%=026^IH\;J>JLI((]ZY<2FXI+NCT,O:4Y.2NDF7/VXOVY]2^*G[=?[
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MJ=$EM_P5!_X)T1QHL<<>I!551@*!-IP  ]*A59_E^)I]7I-V2_F6_8J^$/\
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MD6F2AL4\-FHE>G4FBTR0'%2))4*O3LU!:985J>K9JLDF*E5LT&JD3J]/5L5
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M!(51N=V2-'=3EHK[*!2Q3=E4?WL[4_'WQ@/^6?A[_P  IO\ X_3?^&@/&/\
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MXHE5,<W95)?>>BG]I_Q@/^77P]_X"3?_ !ZD/[47C#_GU\/_ /@)-_\ 'J\
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M*58EEB>4QHX8G+A5]E"YLQ:NJDOO/H$_M5>,!_RY^'O_  %F_P#CU(?VK/&
M_P"7/P]_X#3?_'J\%\=_M8:;\-/B;9Z/KO@/XB:7X9OO$%MX6C\9W-C:PZ'_
M &C<$)!'L:X%\8Y)WC@6X6U,!DD7]YLRXW/B1^T/X0^&/[2'P[^%-])>3>,/
MB8E_-IEO;1K(EM#9V[3R37!+ QHP1D0@,7<, ,([+7+A?Y43[3,?^?DOO/7#
M^U?XP'_+GX?_ / 6;_X[2']K'Q@/^7+P]_X#3?\ QVLUO"?^S49\)_[/Z5?L
ML-_(C+ZQC_\ GZS5_P"&M/&'_/CX?_\  :;_ ..TT_M;>, /^/+P]_X#3?\
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MAJS^%T5G%JGA[Q)K'AR%[O\ M:9S;O=:?<0>8PC8/Y3NV 0VWH:]F7QS"/\
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M9?/O=,M[J"TD9(+AMEH-D3M$H11]LCXB6>/^/RV_[^C_ !IZ_$6S'_+Y;?\
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M?A*VC:7>?\*JU/X@3)XI:\GFU.^MK?3[NV.FZG=^;;31WTN$#QR 208;>_\
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M>?\ QVBBCVU3^9_>'U6C_(ON0?\ #"WPK_Z%;_RI7G_QVC_AA;X5_P#0K?\
ME2O/_CM%%'MJG\S^\/JM'^1?<@_X86^%?_0K?^5*\_\ CM'_  PM\*_^A6_\
MJ5Y_\=HHH]M4_F?WA]5H_P B^Y!_PPM\*_\ H5O_ "I7G_QVC_AA;X5_]"M_
MY4KS_P".T44>VJ?S/[P^JT?Y%]R#_AA;X5_]"M_Y4KS_ ..T?\,+?"O_ *%;
M_P J5Y_\=HHH]M4_F?WA]5H_R+[D'_#"WPK_ .A6_P#*E>?_ !VC_AA;X5_]
M"M_Y4KS_ ..T44>VJ?S/[P^JT?Y%]R#_ (86^%?_ $*W_E2O/_CM'_#"WPK_
M .A6_P#*E>?_ !VBBCVU3^9_>'U6C_(ON0?\,+?"O_H5O_*E>?\ QVC_ (86
M^%?_ $*W_E2O/_CM%%'MJG\S^\/JM'^1?<@_X86^%?\ T*W_ )4KS_X[1_PP
MM\*_^A6_\J5Y_P#':**/;5/YG]X?5:/\B^Y!_P ,+?"O_H5O_*E>?_':/^&%
MOA7_ -"M_P"5*\_^.T44>VJ?S/[P^JT?Y%]R#_AA;X5_]"M_Y4KS_P".T?\
M#"WPK_Z%;_RI7G_QVBBCVU3^9_>'U6C_ "+[D'_#"WPK_P"A6_\ *E>?_':/
M^&%OA7_T*W_E2O/_ ([111[:I_,_O#ZK1_D7W(/^&%OA7_T*W_E2O/\ X[1_
MPPM\*_\ H5O_ "I7G_QVBBCVU3^9_>'U6C_(ON0?\,+?"O\ Z%;_ ,J5Y_\
M':/^&%OA7_T*W_E2O/\ X[111[:I_,_O#ZK1_D7W(/\ AA;X5_\ 0K?^5*\_
M^.T?\,+?"O\ Z%;_ ,J5Y_\ ':**/;5/YG]X?5:/\B^Y!_PPM\*_^A6_\J5Y
M_P#':/\ AA;X5_\ 0K?^5*\_^.T44>VJ?S/[P^JT?Y%]R#_AA;X5_P#0K?\
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E7T&QTRQB\BQTZWCM;>/<6\N-%"JN6))P !DDFBBBLSHVT1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>rdnt-20241110.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOauCiaPty552WYkxvmRwffmaLyopsOotCCEgduzWEa4O -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:RDNT="http://radnet.com/20241110" elementFormDefault="qualified" targetNamespace="http://radnet.com/20241110">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://radnet.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20241110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20241110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>rdnt-20241110_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>rdnt-20241110_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://radnet.com/role/Cover" xlink:href="rdnt-20241110.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://radnet.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45732527947664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 10, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RadNet,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000790526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3326724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1510 Cotner Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los
  Angeles<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-7808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RDNT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /:&;%D1M3Z6[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( /:&
M;%F97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ ]H9L61*!WT-"!   <Q   !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /:&
M;%F?H!OPL0(  .(,   -              "  84,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ ]H9L69>*NQS     $P(   L              ( !80\
M %]R96QS+RYR96QS4$L! A0#%     @ ]H9L6:K$(A8S 0  (@(   \
M         ( !2A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /:&;%DD
M'INBK0   /@!   :              "  :H1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( /:&;%EED'F2&0$  ,\#   3
M      "  8\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' -D3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="radnet_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://radnet.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="radnet_8k.htm">radnet_8k.htm</File>
    <File>rdnt-20241110.xsd</File>
    <File>rdnt-20241110_lab.xml</File>
    <File>rdnt-20241110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "radnet_8k.htm": {
   "nsprefix": "RDNT",
   "nsuri": "http://radnet.com/20241110",
   "dts": {
    "inline": {
     "local": [
      "radnet_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "rdnt-20241110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rdnt-20241110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rdnt-20241110_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://radnet.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "radnet_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "radnet_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001683168-24-007907-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-24-007907-xbrl.zip
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MU5V*9"1=F="?$".IY?\#4$L#!!0    ( /:&;%D9TOFAKDP  %E' P 1
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MZG5B/6%C07C[O16TR^#]$5V_Y2G ,]MQ=*9;G]_JU*]1STC#UO\#R*5H!.F
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M+K4^O.$/H&)['CC5O"E8\)#?A)=;+KQ]\S,NU==W6+@:<,"#3FQJF^'1<0]
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MR.(#(U#'A&C_ 0>V%/.[2?$ XC&:O/<,R&6OU1<*6Q0DP NR/EUI1/_K)HA
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M($M4J:007UO:BP#-JDI[UQ8K2%!]-(8]N VS5*)R,3=&C4+W=+-=SI&=:.W
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M!._9\7JP3775?@[5Z5;2?6KILJ"VE4(G%?<PYK?(2.I;HQ'>B\6;(EFC3Y;
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MC7260\&75*7E4JS;WTL1MN<9UT=9E2J1(UGJ-#0-W''SHJ\Z0Z*/QFK?)=:
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M(RB9HU_SY7 &8?&MQ-X/9Y)4)W#R1W(SYLKF [E20:"N>R"WYH';W#N$K^I
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M/%"]8=DKQ5)U:UF%O*0;1=).4-]\;B0XU(OS-&XI@=8KE"-JSAC --Z&!MO
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MK(-1!:U+YV%\SJ/X)KXZ7RO\M5ZQ7]^O<8; U*=\:-!]K@Y$A()?;AD,+30
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M44SLG1:D9%87ECR1K?;,T5Z@$S5%5['1KP\]<.F.EJS5#.TEBQ^K0!L][[@
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ML4P%J6M6*"23<B\6ZOMPIYR^ \Y4$)5:$R&_\3*]$_[8KWT;B#P/V5V]H"/
MBAJ9=A)Q[]A)";KZJL.8ZI#-"+CB$E4:SF8-#T0'+!.'2C\.9?JQ6J%@MVQ
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MN4\U]]+EXBW$4O/@$.YW=V&$3$Y^$AX?UO(F%Y9124Y"5[A2<@0X6.IQWR3
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M2I01 I6_L/WFK4%#P]<K%%<-+G#ELXJUWS,M].;JYO#;X(D'&X TH[KYGDA
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M!(4E&2+;\2B=><B<<:"-20>==@[UM!&-FU?<RURRF/WVF[1>6PZQ,=I?C*.
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M/"5%."7@*QTM8-[.:)9?8E%.>%7XVW>^3E@9_R7<T!?+O$9YTL()YBIP\""
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M.]KNQ?;C*\X>%;=DA[_ &4GS[[;+<FX\!CNTAK[^#_VV-\BQ4!JU-Q*PY]!
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M\!+IHGG1H2:_QV+(>E30&PU2WG3N@+"08*6TJ:BXLX-8,E6IL4=NV"[ "?I
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MW^6._EQMOL8KDHZ05 H^P':=MNJJ@B:NS=X1GK#XDK[/M1[MR;[X[O#\?VA
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M^X?DDL:#$*EU?@#1;-KQJ$0!PM%VUH>&4/L$XRK)(IR67J[$MJRC>1:M:T!
MNSHDAC H4"!W("QE@&*F"/$*S+\(YL-P:2C]P&)8M:-2RP($1??6AXG4>X%D
MMN6\Y1J><6"ILYNR/6;K^[. +@A0>LP9=VU+>0L43S/0)<V3?"^?I[O9;E:$
M6QIG2ERQ 9E33.CE0;  F-(9*&5(ZE I]-+SZBX!S>5#C&!S=)E; NPFVQ2T
M-0&18#4&T'#0%L^4>B%B)D8FCM,YC<GN9[('VV7HW#(!V&Q#H8D"HL+N#,"B
M$J-"C83<"QAW/-E@OE\D4<]480K=H@$9;;.AJP*" [ &T%&IT6(^\SF3+/%N
M'@M0DX>D?!Z\AQ)0[Q:6'MMM9@!Q0.AT.P0($D&H'>43I#F-&']FC<<=9FPK
M!L#]C,7P"J4GRBU4@YK01JLS)"# AO@$,&N%?BB?24%,OL=35(!D#5Z(NXAC
M<:"RZI_KA))CL/U6K5NZ.NRVF;(( R()=@?P4RD_J ](QJ!;&@HTTS<T=>H?
MFNE0:*9!0S-]#S3+5Q8(-"=O:.J)?VA.AD)S$C0T)^^"1G2\U[%F)C[>\B5[
MM3V<#2J](&-:M0)SD(6'B^&M#Q89(-<S,L0G)L7"ZI;?<?:2T A>,D-R+\
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M-Y9N:8YY\2XYMXU,@,XM.8#--C&:*"!2[,X 0FHQ*M5^7M NLT?4BZSR=X?
M!D)RQZ]K=YK6WMJV:@-BIM,@] YWE?/CL#8NHSR]8ID3^7L1R0OY@G-<>0/;
M"\E=OU3995I_F]*F#0BA3H/@^Y-UC$P5@Q53WE+&\)E8:JU9QU/BFLI]XAC#
MHID[II8$A(?-5T<&&8Z4U@L+BPU.T\_;+*$D@R<B3>66!:O%-@LM24 LV'P!
M+!12I+1>6+C<$+X6T]M/G+WFCU5^5K!M@-HM&YV6VXQ8I0&QTN4/8$:%H#)&
MI=3U \_ND%"\S+((M]0B=8P-:%9CQM"%! QDSJ E)9&\WG+#<K1DZ&M&4/Y(
MT&7U,W3-3/!E/;Y^:22*Y L1Y:J<QIC;$.H2.__5$="P\=LCAC((D'KMP;]#
M4D<@%>*8FEO!,&^>QQ4FYCG9@&\[](>X(FBH><51GSX(F@::U)DJPMHGUT4@
MDI$^LQDUD]O#2[R6R/'*V&)06Q@W%$$P MJ"EL7-WPKPDSMONTJ3Z"IE&+[*
MTM(XSIAGVM.2Y1T$ 1%@NH)2Y!5"5"B]]/]G3)_X]CF/]G><183(IZRR>K3J
MN_XV,-HM,V]J4INF0:$!<?86OP"!ARI0HXX/C1G+Y\4\^="XS.;&HJ?%(Q8'
M\':;9W(&%<;@J^"=08YO+PQH@':3H2,B(/0&V(1N.!21J C]@,I@U(CV='Z6
M';( DOCS_IX\$"[?.UB27?Y9[.BIXPQC0*SKL[?!S=%/YGH#@X#PK6ZA4[T,
M-2M *_F,6%4%^DU6@HI:;+]?WMQT+3Z)S6J3^&N%,R*V_!=02P,$%     @
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M?"# C]5 XK^C7GAX/"(A'\\IYRY](P*TEU?I@=C_P,3N]_D*P-\\N_.[/;7
MV>\4 >+_\[7@/W*+%(%[JIA,["E= =@?B8'4SS"I>QRB\KX1"93V5@K.?_!A
M']A#0CUD.B:\Z-'0;M-AW!5R*'*4G+/6)BKV?RE18.@[8BARE#2TQF+#P >9
M4GN="8XJ?C44.4H"6F>R8>8WPC"S=O?[/V?IY,>-TWW6QRHH8Y2DTV<*A6UY
MIT$8]Q@CQ/=0"66,DFN&S*%P'E@_BO"12.CJ(UV'0!])H:11<LR@/134]XJE
M1*W'+*X?-(ZU4-@HF678( KM1[(:)=85F[+B06 ]=&\1*'N4M!)D%R4$(Q%+
MM9 [MXL',K/'XWH@D^"07E,0&@Z4?/,%UE&"<I4D%I?>_+EE@O9"H:B4@Y\1
MX04@8/.58.^_#'L?CATE#ZVU^4JPG[X,^RD<.THN6FL3$_O ?KQ3CW+I>0+M
M%4.1H^2B-18Q@>=GFCMUK^0S*^9#U5$_*@%%CYBBALVB[O#%21ZRMY=**&_$
M=+7:'";G>ZD-X?^Q1=V59+4>RAPQ<0T9;?H&8Q%W=]/"-Y7H0 +EBY*K5MII
M&JF+L*+$O_ON*Z! 41+0*C,-\[R5[MG'7(K@_=AC%90K2B;I,]7TP.NF$6OO
MH;_S-7@&&\JP>FBC88S?%#.V!P.9IIG8W*/Q/!7S2*%X4=*_H+V&48\E9S$S
M3,P^V2M$Q0BOYERE@T)&2?;\QAHF?*^HBS2UE]WY/"ZWSD#=3:>^D3>DAQ)'
MR?7JC>*2'VF=4?52_A6EH%% 2?N@IIL>9VB<V6%OW>M/'MV*&<\H<Z2"LD9)
M^7RF&F;[63XJXM;IC=?I1'+_\I!*(90P2H(7L-8PY+U^5.,]D$#!HF1VE7:0
MQH2;53PG8D;]LQ>JE5# *)E>R!S:V#L#C;VS%XZ]*!F?SQ02VV)NN#VB[B:<
MS8A_)5FP 'B=#2;Q@-6FU^_E2W[<"FZ5YOT8V@_5V#U2*'"<)9(A>TVCSA)F
M:%)T:<@$$;%-J;;KVCS9>7TI: !PUE "3:/<WO]&.?\HY%*,*=%2T*2XU _=
MX?<6@48!\1EBC5V4$'R5/+.45#X15'F. 8\4BASQV:'''L[<RV)2\_;<4[RJ
M(T3<5P(*'O$A8M@LTOPT0UV?V3-]3PS9]##$WU<"RA_Q@6+8+-K\>36P)YZ9
M##\S/Q!":2-.A:VTA@)YG!+.KS/-!-7!L>5 "(6,..>UTAH*Y)N4JID=U#XH
MN33SS=K.$&Q/ 2ATQ)FM0:LX\%<_UI$7Z]^"Y"O4X+<3(&+WFL1Z[48<NXD4
MQ9E<)$1YJ(?T4.ZH"RO]1ALF?V?F5.U>/^6=&=F\+33IH;X4- HHZ2K4-,ZY
M=6<E?_#4NJ>#\D9,3*N,X:R9RB:<Q4,N2?"Z?$\&Y8N8A5;80L%[3<23RA8F
M7M\K&5/J'I_H[=$&2(B %4!#@IB?O@@%SNT"F:9N,9&,G\9S:UK?929_<ZGM
M7_"F0; <-#28BS@!QI&N@O2/A5XTN5X_T"E5;IK"(UV9:]O04_BB"% <&A_4
M-PJ!,52$Z:)[Y.O6;G#OIBV^<;_<^U?MEO\!4$L! A0#%     @ ]H9L67E+
M;;#/%   EY@   T              ( !     ')A9&YE=%\X:RYH=&U02P$"
M% ,4    " #VAFQ9&=+YH:Y,  !91P, $0              @ 'Z%   <F%D
M;F5T7V5X.3DP,2YH=&U02P$"% ,4    " #VAFQ9ZV4!FB%1  !)J $ $0
M            @ '780  <F%D;F5T7V5X.3DP,BYH=&U02P$"% ,4    " #V
MAFQ95!#$."4#  #="P  $0              @ $GLP  <F1N="TR,#(T,3$Q
M,"YX<V102P$"% ,4    " #VAFQ9%0.^.OX*  " A@  %0
M@ %[M@  <F1N="TR,#(T,3$Q,%]L86(N>&UL4$L! A0#%     @ ]H9L64F$
MGN=4!P  T5<  !4              ( !K,$  ')D;G0M,C R-#$Q,3!?<')E
:+GAM;%!+!08     !@ & 'X!   SR0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>radnet_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rdnt-20241110.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000790526</identifier>
        </entity>
        <period>
            <startDate>2024-11-10</startDate>
            <endDate>2024-11-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-10" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-10" id="Fact000004">0000790526</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-10" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-10" id="Fact000010">2024-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-10" id="Fact000011">RadNet, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-10" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-10" id="Fact000013">001-33307</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-10" id="Fact000014">13-3326724</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-11-10" id="Fact000015">1510 Cotner Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-11-10" id="Fact000016">Los   Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-11-10" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-11-10" id="Fact000018">90025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-11-10" id="Fact000019">310</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-10" id="Fact000020">478-7808</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-10" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-10" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-10" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-10" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-11-10" id="Fact000025">Common     Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-11-10" id="Fact000026">RDNT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-11-10" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-10" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
